AgroFresh Solutions (AGFS) 10-Q 5 Nov 20 2020 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2020	Oct. 22, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	001-36316
Entity Registrant Name	AgroFresh Solutions, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4007249
Entity Address, Address Line One	510-530 Walnut Street, Suite 1350
Entity Address, City or Town	Philadelphia
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19106
City Area Code	267
Local Phone Number	317-9139
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	AGFS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		53,054,960
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001592016

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 25,149	$ 29,288
Accounts receivable, net of allowance for doubtful accounts of $2,025 and $2,232, respectively	69,580	68,634
Inventories	24,444	22,621
Other current assets	17,265	11,802
Total Current Assets	136,438	132,345
Property and equipment, net	13,275	13,177
Goodwill	6,605	6,323
Intangible assets, net	599,236	631,369
Deferred income tax assets	10,502	10,317
Other assets	11,449	12,161
TOTAL ASSETS	777,505	805,692
Current Liabilities:
Accounts payable	13,784	15,105
Current portion of long-term debt	3,316	4,675
Income taxes payable	7,629	5,648
Accrued expenses and other current liabilities	26,665	24,350
Total Current Liabilities	51,394	49,778
Long-term debt	264,850	398,064
Other noncurrent liabilities	5,989	7,246
Deferred income tax liabilities	35,577	16,574
Total Liabilities	357,810	471,662
Commitments and contingencies (see Note 20)
Series B convertible preferred stock, par value $0.0001; 150,000 and 0 shares authorized, 150,000 and 0 shares designated and outstanding at September 30, 2020 and December 31, 2019, respectively	140,684	0
Stockholders’ Equity:
Common stock, par value $0.0001; 400,000,000 shares authorized, 53,054,960 and 51,839,527 shares issued and 52,393,579 and 51,178,146 outstanding at September 30, 2020 and December 31, 2019, respectively	5	5
Preferred stock, par value $0.0001; 1 share authorized and outstanding at September 30, 2020 and December 31, 2019, respectively	0	0
Treasury stock, par value $0.0001; 661,381 shares at September 30, 2020 and December 31, 2019, respectively	(3,885)	(3,885)
Additional paid-in capital	559,037	561,006
Accumulated deficit	(241,710)	(199,621)
Accumulated other comprehensive loss	(41,164)	(31,060)
Total AgroFresh Stockholders’ Equity	272,283	326,445
Non-controlling interest	6,728	7,585
Total Stockholders' Equity	279,011	334,030
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY	$ 777,505	$ 805,692

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Allowance for doubtful accounts	$ 2,025	$ 2,232
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	53,054,960	51,839,527
Common stock, shares outstanding (in shares)	52,393,579	51,178,146
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	1	1
Preferred stock, shares outstanding (in shares)	1	1
Treasury stock (in shares)	661,381	661,381
Treasury Stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Series B Convertible Stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	150,000	0
Preferred stock, shares outstanding (in shares)	150,000	0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Net sales	$ 52,770	$ 48,972	$ 105,775	$ 109,095
Cost of sales (excluding amortization, shown separately below)	13,511	13,892	28,492	31,516
Gross Profit	39,259	35,080	77,283	77,579
Research and development expenses	2,852	2,566	8,389	9,720
Selling, general and administrative expenses	13,494	14,998	39,925	47,044
Amortization of intangibles	10,973	11,754	32,866	35,136
Impairment of long lived assets	0	0	0	992
Change in fair value of contingent consideration	0	(229)	0	128
Grant income	0	0	(2,974)	0
Operating income (loss)	11,940	5,991	(923)	(15,441)
Other income (expense)	96	(81)	1,596	(119)
Debt modification and extinguishment expenses	(5,028)	0	(5,028)	0
Gain (loss) on foreign currency exchange	1,390	54	2,466	(2,884)
Interest expense, net	(4,922)	(8,606)	(18,401)	(26,021)
Gain (loss) before income taxes	3,476	(2,642)	(20,290)	(44,465)
Income taxes expense (benefit)	25,857	(5,653)	22,656	(12,530)
Net (loss) income including non-controlling interests	(22,381)	3,011	(42,946)	(31,935)
Less: Net loss attributable to non-controlling interests	(494)	(278)	(857)	(336)
Net (loss) income attributable to AgroFresh Solutions, Inc	(21,887)	3,289	(42,089)	(31,599)
Less: Dividends on convertible preferred stock	4,400	0	4,400	0
(Loss) income attributable to AgroFresh Solutions, Inc. common stockholders	$ (26,287)	$ 3,289	$ (46,489)	$ (31,599)
Net (loss) income per share:
Basic (in dollars per share)	$ (0.52)	$ 0.06	$ (0.92)	$ (0.64)
Diluted (in dollars per share)	$ (0.52)	$ 0.06	$ (0.92)	$ (0.64)
Weighted average shares outstanding:
Basic (in shares)	51,001,852	50,227,590	50,765,829	50,138,835
Diluted (in shares)	51,001,852	50,288,304	50,765,829	50,138,835

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (22,381)	$ 3,011	$ (42,946)	$ (31,935)
Other comprehensive (loss) income:
Unrealized gain (loss) on hedging activity, net of tax of $61, $24, ($81) and $24, respectively	229	83	(304)	83
Recognition of gain on hedging activity reclassified to net loss, net of tax of ($239), ($78), ($398) and ($235), respectively	(857)	(278)	(1,411)	(834)
Foreign currency translation adjustments	296	(3,823)	(8,389)	(903)
Comprehensive loss, net of tax	$ (22,714)	$ (1,007)	$ (53,050)	$ (33,589)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Unrealized gain on hedging activity, tax expense (benefit)	$ 61	$ 24	$ (81)	$ 24
Realized gain on hedging activity reclassified to net loss, tax	$ (239)	$ (78)	$ (398)	$ (235)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Non-Controlling Interest
Beginning balance (in shares) at Dec. 31, 2018		1	51,071,573
Beginning balance at Dec. 31, 2018	$ 372,576	$ 0	$ 5	$ (3,885)	$ 535,819	$ (138,789)	$ (28,837)	$ 8,263
Increase (Decrease) in Stockholders' Equity
Stock-based compensation	2,256				2,256
Issuance of stock, net of forfeitures (in shares)			521,386
Comprehensive loss	(33,589)					(31,599)	(1,654)	(336)
Ending balance (in shares) at Sep. 30, 2019		1	51,592,959
Ending balance at Sep. 30, 2019	341,243	$ 0	$ 5	(3,885)	538,075	(170,388)	(30,491)	7,927
Beginning balance (in shares) at Jun. 30, 2019		1	51,620,770
Beginning balance at Jun. 30, 2019	341,434	$ 0	$ 5	(3,885)	537,259	(173,677)	(26,473)	8,205
Increase (Decrease) in Stockholders' Equity
Stock-based compensation	816				816
Forfeiture of stock, net of issuances (in shares)			(27,811)
Comprehensive loss	(1,007)					3,289	(4,018)	(278)
Ending balance (in shares) at Sep. 30, 2019		1	51,592,959
Ending balance at Sep. 30, 2019	341,243	$ 0	$ 5	(3,885)	538,075	(170,388)	(30,491)	7,927
Beginning balance (in shares) at Dec. 31, 2019		1	51,839,527
Beginning balance at Dec. 31, 2019	334,030	$ 0	$ 5	(3,885)	561,006	(199,621)	(31,060)	7,585
Increase (Decrease) in Stockholders' Equity
Stock-based compensation	2,473				2,473
Issuance of stock, net of forfeitures (in shares)			1,178,663
Shares withheld for taxes (in shares)			(47,599)
Shares withheld for taxes	(239)				(239)
Issuance of common stock under employee stock purchase plan (in shares)			84,369
Issuance of common stock under employee stock purchase plan	197				197
Convertible preferred dividend	(4,400)				(4,400)
Comprehensive loss	(53,050)					(42,089)	(10,104)	(857)
Ending balance (in shares) at Sep. 30, 2020		1	53,054,960
Ending balance at Sep. 30, 2020	279,011	$ 0	$ 5	(3,885)	559,037	(241,710)	(41,164)	6,728
Beginning balance (in shares) at Jun. 30, 2020		1	52,875,089
Beginning balance at Jun. 30, 2020	305,272	$ 0	$ 5	(3,885)	562,584	(219,823)	(40,831)	7,222
Increase (Decrease) in Stockholders' Equity
Stock-based compensation	872				872
Issuance of stock, net of forfeitures (in shares)			187,302
Shares withheld for taxes (in shares)			(7,431)
Shares withheld for taxes	(19)				(19)
Issuance of common stock under employee stock purchase plan (in shares)			0
Issuance of common stock under employee stock purchase plan	0				0
Convertible preferred dividend	(4,400)				(4,400)
Comprehensive loss	(22,714)					(21,887)	(333)	(494)
Ending balance (in shares) at Sep. 30, 2020		1	53,054,960
Ending balance at Sep. 30, 2020	$ 279,011	$ 0	$ 5	$ (3,885)	$ 559,037	$ (241,710)	$ (41,164)	$ 6,728

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (42,946)	$ (31,935)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	34,775	36,692
(Benefit) provision for bad debts	(124)	215
Stock-based compensation	2,473	2,256
Impairment of intangible assets	0	992
Amortization of deferred financing costs	2,342	2,032
Interest income on interest rate swap	(1,809)	(1,070)
Accretion of contingent consideration	0	2,669
Change in fair value of contingent consideration	0	128
Deferred income taxes	18,086	(14,499)
Loss on sales of property and equipment	155	2
Changes in operating assets and liabilities:
Accounts receivable	(4,297)	(1,499)
Inventories	(2,281)	(4,424)
Prepaid expenses and other current assets	(6,784)	(1,429)
Accounts payable	(1,274)	3,855
Accrued expenses and other liabilities	2,344	(2,958)
Income taxes payable	2,846	(95)
Other assets and liabilities	(3,865)	384
Net cash used in operating activities	(359)	(8,684)
Cash flows from investing activities:
Cash paid for property and equipment	(2,131)	(3,271)
Other investments	0	(250)
Net cash used in investing activities	(2,131)	(3,521)
Cash flows from financing activities:
Net proceeds from issuance of convertible preferred stock	145,490	0
Costs associated with issuance of convertible preferred stock	(7,006)	0
Payment of preferred dividends	(2,200)	0
Proceeds from long-term debt	2,042	0
Repayment of long-term debt	(131,599)	(5,056)
Payment of deferred financing costs	(7,988)	0
Proceeds from issuance of stock under employee stock purchase plan	259	0
Net cash used in financing activities	(1,002)	(5,056)
Effect of exchange rate changes on cash and cash equivalents and restricted cash	(1,176)	1,682
Net decrease in cash and cash equivalents and restricted cash	(4,668)	(15,579)
Cash and cash equivalents and restricted cash, beginning of period	29,817	34,852
Cash and cash equivalents, end of period	25,149	19,273
Cash paid for:
Cash paid for interest	18,381	18,007
Cash paid for income taxes	1,733	2,469
Supplemental schedule of non-cash investing and financing activities:
Accrued purchases of property and equipment	$ 146	$ 62

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business AgroFresh Solutions, Inc. (the “Company”) is a global leader in delivering innovative food preservation and waste prevention solutions for fresh produce. The Company is empowering the food industry with a range of integrated solutions designed to help growers, packers and retailers improve produce freshness and quality while preventing waste. The Company has an extensive portfolio of solutions to extend freshness across the produce supply chain from near-harvest up to the point-of-sale. These include Harvista TM for near-harvest optimization and the SmartFresh TM Quality System, the Company's flagship post-harvest freshness solution. Additional post-harvest freshness solutions include fungicides that can be applied to meet various customer operational requirements in both foggable (ActiMist™) and liquid (ActiSeal™) delivery options. The Company has a controlling interest in Tecnidex Fruit Protection, S.A. (“Tecnidex”), a leading regional provider of post-harvest fungicides, waxes, disinfectants and packinghouse equipment for the citrus market. Beyond apples, SmartFresh technology can provide ready-to-eat freshness for other fruits and vegetables including avocados, bananas, melons, tomatoes, broccoli and mangos. Additionally, LandSpring TM eases transplant shock for higher potential yields. RipeLock TM is the Company's modified atmosphere packaging technology for fruits and vegetables. The Company has key products registered in over 50 countries and supports customers with over 25,000 storage rooms globally. The end-markets that the Company serves are seasonal and are generally aligned with the seasonal growing patterns of the Company’s customers. For those customers growing, harvesting or storing apples and pears, the Company’s core crops, the peak season in the southern hemisphere is the first and second quarters of each year, while the peak season in the northern hemisphere is the third and fourth quarters of each year. Within each half-year period (i.e., January through June for the southern hemisphere, and July through December for the northern hemisphere) the growing season has historically occurred during both quarters. A variety of factors, including weather and fruit quality, may affect the timing of the growing, harvesting and storing patterns of the Company’s customers and therefore shift consumption of the Company’s services and products between the first and second quarters primarily in the southern hemisphere or between the third and fourth quarters primarily in the northern hemisphere.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission. These financial statements include all adjustments that are necessary for a fair presentation of the Company's condensed consolidated results of operations, financial condition and cash flows for the periods shown, including normal, recurring accruals and other items. The condensed consolidated results of operations for the interim periods presented are not necessarily indicative of results for the full year. For additional information, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report filed on Form 10-K for the year ended December 31, 2019. COVID-19 In March 2020, the World Health Organization characterized the coronavirus ("COVID-19") a pandemic, and the President of the United States declared the COVID-19 outbreak a national emergency. The rapid spread of the pandemic and the continuously evolving responses to combat it have had an increasingly negative impact on the global economy. During the three months ended September 30, 2020, as the Company’s primary sales regions moved to the northern hemisphere, the COVID-19 pandemic continued to not have a significant adverse impact on the Company’s results of operations. However, there were numerous obstacles presented and some localized financial impacts of the pandemic, including fluctuations in foreign currency exchange rates and customer demand and spending pattern changes. While the Company is following the requirements of governmental authorities and taking additional preventative and protective measures to ensure the safety of its workforce, including implementing remote working arrangements and varying procedures for essential workforce, the Company cannot be 100% certain there will not be any incidents across its global operations that may cause service interruptions. The rapid development and fluidity of this situation precludes any prediction as to the ultimate material adverse impact of the coronavirus outbreak, although the Company operates in an industry that thus far has not been as severely impacted as others. Nevertheless, the outbreak presents some uncertainty and risk with respect to the Company and its performance and financial results. Adoption of Highly Inflationary Accounting in Argentina GAAP requires the use of highly inflationary accounting for countries whose cumulative three-year inflation rate exceeds 100 percent. The Company closely monitors the inflation data and currency volatility in Argentina, where there are multiple data sources for measuring and reporting inflation. In the second quarter of 2018, the Argentine peso rapidly devalued relative to the U.S. dollar, which along with increased inflation, indicated that the three-year cumulative inflation rate in that country exceeded 100 percent as of June 30, 2018. As a result, the Company adopted highly inflationary accounting as of July 1, 2018 for its subsidiary in Argentina. Under highly inflationary accounting, the functional currency of the Company's subsidiary in Argentina became the U.S. dollar, and its income statement and balance sheet are measured in U.S. dollars using both current and historical rates of exchange. The effect of changes in exchange rates on Argentine peso-denominated monetary assets and liabilities are reflected in earnings. As the three-year cumulative inflation rate exceeded 100 percent as of September 30, 2020, there is no change to highly inflationary accounting. As of September 30, 2020, the Company’s subsidiary in Argentina had a net asset position of $3.0 million. Net sales attributable to Argentina were approximately 6% and 6% of the Company’s consolidated net sales for each of the nine months ended September 30, 2020 and 2019, respectively. Disaggregation of Revenue The Company disaggregates revenue from contracts with customers into geographic region, product and timing of transfer of goods and services. The Company determined that disaggregating revenue into these categories achieves the disclosure objective of depicting how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. Revenues for the three months ended September 30, 2020 (in thousands) Region North America EMEA Latin America Asia Pacific (4) Total Revenues Product 1-MCP based $ 17,122 $ 28,906 $ 845 $ 1,165 $ 48,038 Fungicides, waxes, coatings and disinfectants 534 3,011 575 — 4,120 Other* 190 115 210 97 612 $ 17,846 $ 32,032 $ 1,630 $ 1,262 $ 52,770 Pattern of Revenue Recognition Products transferred at a point in time $ 17,663 $ 31,921 $ 1,420 $ 1,165 $ 52,169 Services transferred over time 183 111 210 97 601 $ 17,846 $ 32,032 $ 1,630 $ 1,262 $ 52,770 Revenues for the three months ended September 30, 2019 (in thousands) Region North America EMEA Latin America Asia Pacific (4) Total Revenues Product 1-MCP based $ 19,726 $ 22,377 $ 1,680 $ 1,605 $ 45,388 Fungicides, waxes, coatings and disinfectants — 2,857 198 — 3,055 Other* 218 86 108 117 529 $ 19,944 $ 25,320 $ 1,986 $ 1,722 $ 48,972 Pattern of Revenue Recognition Products transferred at a point in time $ 19,802 $ 25,238 $ 1,877 $ 1,605 $ 48,522 Services transferred over time 142 82 109 117 450 $ 19,944 $ 25,320 $ 1,986 $ 1,722 $ 48,972 Revenues for the nine months ended September 30, 2020 (in thousands) Region North America EMEA Latin America Asia Pacific (4) Total Revenues Product 1-MCP based $ 19,264 $ 37,223 $ 23,217 $ 11,538 $ 91,242 Fungicides, waxes, coatings and disinfectants 534 9,650 1,750 — 11,934 Other* 722 700 938 239 2,599 $ 20,520 $ 47,573 $ 25,905 $ 11,777 $ 105,775 Pattern of Revenue Recognition Products transferred at a point in time $ 19,823 $ 46,887 $ 25,338 $ 11,538 $ 103,586 Services transferred over time 697 686 567 239 2,189 $ 20,520 $ 47,573 $ 25,905 $ 11,777 $ 105,775 Revenues for the nine months ended September 30, 2019 (in thousands) Region North America EMEA Latin America Asia Pacific (4) Total Revenues Product 1-MCP based $ 23,084 $ 31,965 $ 27,503 $ 11,287 $ 93,839 Fungicides, waxes, coatings and disinfectants — 11,365 1,458 — 12,823 Other* 954 927 381 171 2,433 $ 24,038 $ 44,257 $ 29,342 $ 11,458 $ 109,095 Pattern of Revenue Recognition Products transferred at a point in time $ 23,380 $ 43,374 $ 29,159 $ 11,309 $ 107,222 Services transferred over time 658 883 183 149 1,873 $ 24,038 $ 44,257 $ 29,342 $ 11,458 $ 109,095 *Other includes FreshCloud, technical services and sales-type leases related to Tecnidex. ——————————————————————————————————— (1) North America includes the United States and Canada. (2) EMEA includes Europe, the Middle East and Africa. (3) Latin America includes Argentina, Brazil, Chile, Costa Rica, Colombia, Dominican Republic, Ecuador, Guatemala, Mexico, Peru and Uruguay. (4) Asia Pacific includes Australia, China, India, Japan, New Zealand, the Philippines, South Korea, Taiwan and Thailand. Contract Assets and Liabilities ASC 606 requires an entity to present a revenue contract as a contract asset when the entity performs its obligations under the contract by transferring goods or services to a customer before the customer pays consideration or before payment is due. ASC 606 also requires an entity to present a revenue contract as a contract liability in instances when a customer pays consideration, or an entity has a right to an amount of consideration that is unconditional (e.g., receivable), before the entity transfers a good or service to the customer. The following table presents changes in the Company’s contract assets and liabilities during the nine months ended September 30, 2020 and the year ended December 31, 2019: (in thousands) Balance at Additions Deductions Balance at Contract assets: Unbilled revenue $ 1,666 11,670 (9,423) $ 3,913 Contract liabilities: Deferred revenue $ 1,175 4,437 (4,239) $ 1,373 (in thousands) Balance at Additions Deductions Balance at Contract assets: Unbilled revenue $ 1,956 10,029 (10,319) $ 1,666 Contract liabilities: Deferred revenue $ 1,280 3,032 (3,137) $ 1,175 The Company recognizes contract assets in the form of unbilled revenue in instances where services are performed by the Company but not billed by period end. The Company recognizes contract liabilities in the form of deferred revenue in instances where a customer pays in advance for future services to be performed by the Company. The Company generally receives payments from its customers based on standard terms and conditions. No significant changes or impairment losses occurred to contract balances during the nine months ended September 30, 2020. Amounts reclassified from unbilled revenue to accounts receivable for the nine months ended September 30, 2020 and for the year ended December 31, 2019 were $9.4 million and $10.3 million, respectively. Amounts reclassified from deferred revenue to revenue for the nine months ended September 30, 2020 and for the year ended December 31, 2019 were $4.2 million and $3.1 million, respectively. Recently Issued Accounting Standards and Pronouncements In January 2017, the Financial Accounting Standards Board ("FASB") issued ASU No. 2017-04, "Intangibles - Goodwill and Other", which simplifies the test for goodwill impairment. The guidance was effective for the Company beginning in the first quarter of fiscal year 2020. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the condensed consolidated financial statements of the Company. In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments”, which introduces a new current expense credit loss model to measure impairment on certain types of financial instruments. This update requires an entity to use a forward-looking expected credit loss model for accounts receivable, loans, and other financial instruments. In addition, the FASB issued various amendments during 2018 and 2019 to clarify the provisions of ASU 2016-13. The standard was effective for fiscal years beginning January 1, 2020, including interim periods. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the financial statements of the Company. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify and add certain disclosure requirements related to fair value measurements covered in Topic 820. The new standard was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the notes to condensed consolidated financial statements of the Company. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments simplify the accounting for income taxes by removing certain exceptions to the general principles of Topic 740, "Income Taxes" and also improve consistent application by clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted, with the amendments to be applied on a retrospective, modified retrospective or prospective basis, depending on the specific amendment. The Company is currently evaluating the impact of adopting this guidance. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments are intended to ease the potential burden in accounting for, or recognizing the effects of, reference rate

Business Combinations and Asset

Business Combinations and Asset Acquisition	9 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Business Combinations and Asset Acquisition	Business Combinations and Asset Acquisition Business Combination with Dow On July 31, 2015 (the "Closing Date"), the Company consummated a business combination (the “Business Combination”) pursuant to the Stock Purchase Agreement, dated April 30, 2015 (the “Purchase Agreement”), by and between the Company and The Dow Chemical Company ("Dow") providing for the acquisition by the Company of the AgroFresh business from Dow, resulting in AgroFresh Inc. becoming a wholly-owned, indirect subsidiary of the Company. Pursuant to the Purchase Agreement, the Company paid the following consideration to Rohm and Haas Company (“R&H”), a subsidiary of Dow: (i) 17.5 million shares of common stock and (ii) $635 million in cash. Pursuant to a Tax Receivables Agreement among the Company, Dow, R&H and AgroFresh Inc. entered into in connection with the consummation of the Business Combination, as amended on April 4, 2017 (as so amended, the “Tax Receivables Agreement”), the Company was required to pay to Dow 50% of the annual tax savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realized as a result of the increase in tax basis of the AgroFresh assets resulting from a Section 338(h)(10) election that the Company and Dow made in connection with the Business Combination. In December 2019, the Tax Receivables Agreement was terminated, and the Company paid to Dow an aggregate of $16 million in settlement of all past and estimated future liabilities that would have been owed under the Tax Receivables Agreement. Based on this termination, the Company recorded a reduction of liabilities of $27.9 million. This reduction, net of deferred income taxes of $5.9 million, has been recorded to additional paid-in capital since the Tax Receivable Agreement was with a related party and is treated as a capital transaction. Acquisition of Tecnidex On November 7, 2017, the Company entered into a definitive agreement to acquire a controlling interest in Tecnidex. The transaction was closed on December 1, 2017. Tecnidex is a leading regional provider of post-harvest fungicides, waxes, coatings, and disinfectants for the citrus market, with clients in 18 countries. For over 35 years, Tecnidex has been helping fruit and vegetable producers offer clean, safe and high-quality products to their regional clients. The acquisition was accounted for as a purchase in accordance with ASC 805, Business Combination . At the effective date of the acquisition, the Company agreed to pay holders of Tecnidex an estimated $25.0 million in cash for 75% of the outstanding capital stock, of which $20.0 million was paid on December 1, 2017. In 2018, the purchase price was finalized as $22.3 million after giving effect to working capital, net debt and other adjustments. The remaining $2.3 million was paid during 2018.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions The Company is a party to an ongoing transition services agreement with Dow, a related party. The Company incurred expenses for such transition services for the nine months ended September 30, 2020 and 2019 of $0.04 million and $0.09 million, respectively. As of September 30, 2020 and December 31, 2019, the Company had outstanding amounts payable to Dow of $0.0 million and $0.1 million, respectively. On June 13, 2020, in connection with the execution of the Investment Agreement (as defined in Note 15- Series B Convertible Preferred Stock and Stockholders’ Equity), the Company, PSP AGFS Holdings, L.P. (the “Investor”) and R&H entered into a side agreement, pursuant to which the parties agreed that if the Investor or its affiliates has the right to designate at least 50% of the total directors on the Company’s board of directors pursuant to the Investment Agreement, so long as R&H or its affiliates beneficially owns at least 20% of the Company’s outstanding common stock (on a fully diluted, “as converted” basis), the Company and the board of directors will increase the size of the board of directors by one member and the board will elect a designee selected by R&H to fill the newly-created vacancy. Such right is in addition to any right that R&H has to appoint a member of the board pursuant to its ownership of the Company’s Series A preferred stock (see Note 15- Series B Convertible Preferred Stock and Stockholders’ Equity). Refer to Note 3 - Business Combinations and Asset Acquisition regarding the contingent consideration owed to Dow as part of the Business Combination, as well as certain other agreements entered into in connection with the Business Combination, including the termination of the Tax Receivables Agreement in 2019. During 2016, the Company made a minority investment in RipeLocker, LLC ("RipeLocker"), a company led by George Lobisser, a director of the Company. In February 2019, the Company made a further minority investment in RipeLocker. As of and for the nine months ended September 30, 2020, there were no material amounts paid or owed to RipeLocker or Mr. Lobisser.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories at September 30, 2020 and December 31, 2019 consisted of the following: (in thousands) September 30, 2020 December 31, 2019 Raw material $ 3,026 $ 3,401 Work-in-process 8,575 7,278 Finished goods 11,619 10,974 Supplies 1,224 968 Total inventories $ 24,444 $ 22,621

Other Current Assets

Other Current Assets	9 Months Ended
	Sep. 30, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets	Other Current Assets The Company's other current assets at September 30, 2020 and December 31, 2019 consisted of the following: (in thousands) September 30, 2020 December 31, 2019 VAT receivable $ 7,627 $ 4,925 Prepaid income tax asset 5,349 3,616 Prepaid and other current assets 4,289 3,261 Total other current assets $ 17,265 $ 11,802

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment at September 30, 2020 and December 31, 2019 consisted of the following: (in thousands, except for useful life data) Useful life September 30, 2020 December 31, 2019 Buildings and leasehold improvements 7-20 $ 7,032 $ 6,508 Machinery & equipment 1-12 11,953 10,954 Furniture 1-12 2,944 2,681 Construction in progress 1,149 902 23,078 21,045 Less: accumulated depreciation (9,803) (7,868) Total property and equipment, net $ 13,275 $ 13,177 Depreciation expense was $0.7 million and $0.6 million for the three months ended September 30, 2020 and 2019, respectively, and $1.9 million and $1.6 million for the nine months ended September 30, 2020 and 2019, respectively. Depreciation expense is recorded in cost of sales, selling, general and administrative expense and research and development expense in the condensed consolidated statements of operations.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible AssetsChanges in the carrying amount of goodwill for the nine months ended September 30, 2020 and the year ended December 31, 2019 were as follows: (in thousands) September 30, 2020 December 31, 2019 Beginning balance $ 6,323 $ 6,670 Foreign currency translation 282 (347) Ending balance $ 6,605 $ 6,323 The Company’s intangible assets at September 30, 2020 and December 31, 2019 consisted of the following: September 30, 2020 December 31, 2019 (in thousands) Gross Carrying Accumulated Impairment Net Gross Carrying Accumulated Impairment Net Other intangible assets: Developed technology $ 798,240 $ (244,918) $ — $ 553,322 $ 758,760 $ (206,998) $ — $ 551,762 In-process research and development — — — — 39,000 (7,222) — 31,778 Trade name 27,158 — — 27,158 27,200 — 27,200 Service provider network 2,000 — — 2,000 2,000 — — 2,000 Customer relationships 18,551 (3,548) — 15,003 18,058 (2,993) — 15,065 Software 10,691 (8,967) — 1,724 9,861 (5,347) (992) 3,522 Other 100 (71) — 29 100 (58) — 42 Total intangible assets $ 856,740 $ (257,504) $ — $ 599,236 $ 854,979 $ (222,618) $ (992) $ 631,369 During 2019, the Company recognized an impairment charge of $1.0 million associated with Verigo software following a partnership agreement with a new technology provider. During the Company's annual impairment testing conducted for the year ended December 31, 2019, the Company accelerated the amortization of Ripelock developed technology based on the Company's remaining expected useful life of the technology. This resulted in an increase to amortization expense of $34.0 million. At September 30, 2020, the weighted-average amortization periods remaining for developed technology, in-process R&D, customer relationships, software and other was 14.8, 14.0, 12.1, 1.0, and 1.8 years, respectively, and the weighted-average amortization period remaining for these finite-lived intangible assets was 14.6 years. Estimated annual amortization expense for finite-lived intangible assets subsequent to September 30, 2020 is as follows: (in thousands) Amount 2020 (remaining) $ 12,045 2021 41,730 2022 40,893 2023 40,791 2024 40,791 Thereafter 393,828 Total $ 570,078 Amortization expense for intangible assets was $11.0 million and $11.8 million for the three months ended September 30, 2020 and 2019, respectively, and $32.9 million and $35.1 million for the nine months ended September 30, 2020 and 2019, respectively.

Other Assets

Other Assets	9 Months Ended
	Sep. 30, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Assets	Other AssetsThe Company’s other assets at September 30, 2020 and December 31, 2019 consisted of the following: (in thousands) September 30, 2020 December 31, 2019 Right-of-use asset $ 5,657 $ 6,599 Long term sales-type lease receivable 2,354 2,501 Other long term receivable 3,438 3,061 Total other assets $ 11,449 $ 12,161

Accrued and Other Current Liabi

Accrued and Other Current Liabilities	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Accrued and Other Current Liabilities	Accrued and Other Current Liabilities The Company’s accrued and other current liabilities at September 30, 2020 and December 31, 2019 consisted of the following: (in thousands) September 30, 2020 December 31, 2019 Accrued compensation and benefits $ 7,111 $ 7,307 Accrued taxes 6,501 3,017 Lease liability 1,368 1,493 Accrued rebates payable 3,001 1,377 Insurance premium financing payable 1,151 1,000 Severance 218 444 Deferred revenue 1,373 1,175 Accrued interest 66 71 Interest rate swap 290 — Other 5,586 8,466 Total accrued and other current liabilities $ 26,665 $ 24,350

Debt

Debt	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Debt	Debt The Company’s debt, net of unamortized deferred issuance costs, at September 30, 2020 and December 31, 2019 consisted of the following: (in thousands) September 30, 2020 December 31, 2019 Total term loan outstanding $ 275,000 $ 405,875 Unamortized deferred issuance costs (9,018) (3,886) Tecnidex loan outstanding 2,184 750 Less: Amounts due within one year 3,316 4,675 Total long-term debt due after one year $ 264,850 $ 398,064 Restated Credit Facility On July 27, 2020, the Company completed a comprehensive refinancing (the “ Refinancing ” ) by (i) entering into an Amended and Restated Credit Agreement (the “Restated Credit Agreement”) with the other loan parties party thereto, Bank of Montreal, as administrative agent and the lenders party thereto, and (ii) consummating the transactions contemplated by the Investment Agreement (as defined and described in Note 15 – Series B Convertible Preferred Stock and Stockholders’ Equity). The Restated Credit Agreement amends and restates in its entirety the Prior Credit Facility (defined below). The Restated Credit Agreement provides for a $25.0 million revolving credit facility (the “Restated Revolving Loan”) which matures on June 30, 2024, and a $275.0 million term credit facility (the “Restated Term Loan” and, together with the Restated Revolving Loan, the “Restated Credit Facility”), which matures on December 31, 2024. The Restated Credit Facility includes a $5.0 million swingline commitment and a $10.0 million letter of credit sub-limit. Loans under the Restated Term Loan bear interest at a rate equal to, at the Company’s option, either the Adjusted Eurodollar Rate for the interest period in effect for such borrowing plus an Applicable Rate of 6.25% per annum, or the Alternate Base Rate plus an Applicable Rate of 5.25% per annum. Loans under the Restated Revolving Loan bear interest at a rate equal to, at the Company’s option, the Adjusted Eurodollar Rate for the interest period in effect for such borrowing plus the Applicable Rate ranging from 6.25% to 6.0% per annum, based on certain ratios. The interest rate was 7.25% for the three months ended September 30, 2020. The Company is also required to pay a commitment fee on the unused portion of the Restated Revolving Loan at a rate ranging from 0.5% to 0.375%, based on certain ratios. The Company is required to make mandatory prepayments of outstanding indebtedness under the Restated Credit Agreement under certain circumstances. The obligations of AgroFresh Inc., a wholly-owned subsidiary of the Company and the borrower under the Restated Credit Facility, are initially guaranteed by the Company and the Company’s wholly-owned subsidiary, AF Solutions Holdings LLC (together with AgroFresh Inc. and the Company, the “Loan Parties”) and may in the future be guaranteed by certain other domestic subsidiaries of the Company. The obligations of the Loan Parties under the Credit Agreement and other loan documents are secured, subject to customary permitted liens and other agreed upon exceptions, by a perfected security interest in all tangible and intangible assets of the Loan Parties, except for certain excluded assets, and equity interests of certain foreign subsidiaries of the Loan Parties held by the Loan Parties (subject to certain exclusions and limitations). The Refinancing was deemed a partial extinguishment of the Term Loan (as defined below) under ASC Topic No. 470-50, “Debt – Modifications and Extinguishments” (Topic No. 470), whereby $107.1 million of the $403.8 million outstanding at the time of the Refinancing was deemed an extinguishment and $296.7 million was deemed a modification of debt. As such, unamortized deferred issuance costs related to the extinguishment of $0.7 million were written off in debt modification and extinguishment expenses and the remaining $1.9 million was deferred and amortized over the term of the Restated Term Loan. In connection with the Restated Term Loan, expenses incurred related to existing lenders of $4.4 million were recognized in debt modification and extinguishment expenses. Expenses to new lenders of $1.1 million were deferred and amortized over the term of the Restated Term Loan along with $6.4 million of lender fees and issue discounts. In total, the Company deferred debt issuance costs of $7.5 million related to the Restated Term Loan, $1.9 million related to the modification of the Term Loan and $0.5 million related to the Restated Revolving Loan. The debt issuance costs associated with the Restated Term Loan were capitalized against the principal balance of the debt, and the Restated Revolving Loan costs were capitalized in Other Assets. All issuance costs will be accreted through interest expense using the effective interest method for the duration of each respective debt facility. The interest expense related to the amortization of the Restated Credit Facility debt issuance costs during the three months ended September 30, 2020 was $0.3 million. As of September 30, 2020 there were $9.0 million of unamortized deferred issuance costs. At September 30, 2020, there was $275.0 million outstanding under the Restated Term Loan and no balance outstanding under the Restated Revolving Loan. At September 30, 2020, the Company evaluated the amount recorded under the Restated Term Loan and determined that the fair value was approximately $267.4 million. The fair value of the debt is based on quoted inactive market prices and is therefore classified as Level 2 within the valuation hierarchy. Certain restrictive covenants are contained in the Restated Credit Agreement, and the Company was in compliance with these covenants as of September 30, 2020. Prior Credit Facility On July 31, 2015, in connection with the consummation of the Business Combination, AgroFresh Inc. as the borrower and AF Solutions Holdings LLC as the guarantor, entered into a Credit Agreement with Bank of Montreal, as administrative agent (as subsequently amended prior to the Refinancing, the “Prior Credit Facility”). The Prior Credit Facility consisted of a $425.0 million term loan (the “Term Loan”), with an amortization equal to 1.00% per year, and a revolving loan facility (the “Revolving Loan”). The net proceeds of the Term Loan were used to fund a portion of the purchase price payable to Dow in connection with the Business Combination. The Revolving Loan included a $10.0 million letter-of-credit sub-facility, issuances against which reduce the available capacity for borrowing. The Term Loan had a scheduled maturity date of July 31, 2021. As discussed above, the Prior Credit Facility was refinanced on July 27, 2020, and there were no amounts outstanding as of September 30, 2020. The interest rates on borrowings under the facilities were either the alternate base rate plus 3.75% or LIBOR plus 4.75% per annum, with a 1.00% LIBOR floor (with step-downs in respect of borrowings under the Revolving Loan dependent upon the achievement of certain financial ratios). As of the Closing Date, the Company incurred approximately $12.9 million in debt issuance costs related to the Term Loan and $1.3 million in costs related to the Revolving Loan. The debt issuance costs associated with the Term Loan were capitalized against the principal balance of the debt, and the Revolving Loan costs were capitalized in Other Assets. The interest expense related to the amortization of the Term Loan debt issuance costs during the three months ended September 30, 2020 and 2019, was approximately $0.2 million and $0.6 million, respectively. The interest expense related to the amortization of the Term Loan debt issuance costs during the nine months ended September 30, 2020 and 2019 was approximately $1.4 million and $1.7 million, respectively. Tecnidex Debt On March 23, 2020, Tecnidex entered into a €1.0 million loan agreement with Banco Santander, S.A., which provides funding through March 2023 at a 1.5% interest rate. In May 2020, Tecnidex entered into a €0.3 million loan agreement with BBVA, which provides funding through May 2025 at a 2.2% interest rate. In July 2020, Tecnidex entered into a €0.6 million loan agreement with Banco Santander, S.A., which provides funding through July 2025 at a 2.5% interest rate. Scheduled principal repayments of debt subsequent to September 30, 2020 are as follows: (in thousands) Amount 2020 (remaining) $ 815 2021 3,348 2022 3,390 2023 3,181 2024 and thereafter $ 266,450 Total $ 277,184 Interest Rate Swap The Company entered into an interest rate swap contract in August 2019 to hedge interest rate risk remaining outstanding with the Restated Credit Facility. During the three and nine months ended September 30, 2020, an unrealized gain of $0.3 million and an unrealized loss of $0.4 million was recognized, respectively, in connection with this swap, which is still outstanding. The interest rate swap contract matures on December 31, 2020. The Company entered into an interest rate swap contract in January 2018 to hedge interest rate risk associated with the Term Loan. The hedge was settled in September 2018 for $4.0 million, which is being amortized through December 31, 2020, the remaining period of the original hedge. PPP Loan As part of the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"), the Company received a Paycheck Protection Program ("PPP") loan to offset eligible costs incurred during the period. Under the terms of the PPP, PPP loans and accrued interest are forgivable after twenty-four weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the forgiveness period. As of September 30, 2020, the Company has used the entire loan proceeds to fund its eligible payroll expenses and mortgage interest, avoiding furlough of office employees. As a result, the Company believes that it has met the PPP eligibility criteria for forgiveness and has concluded that the loan represents, in substance, a government grant that is expected to be forgiven. As such, in accordance with IAS 20 “Accounting for Government Grants and Disclosure of Government Assistance” the Company has recognized the entire loan amount as Grant Income at September 30, 2020. The Company does not anticipate taking any action that would cause any portion of the loan to be ineligible for forgiveness. However, to the extent that any amount is deemed unforgivable, such amount is payable over two

Leases

Leases	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Leases	Leases The Company enters into lease agreements for certain facilities and vehicles that are primarily used in the ordinary course of business. These leases are accounted for as operating leases, whereby lease expense is recognized on a straight-line basis over the term of the lease. Most leases include an option to extend or renew the lease term. The exercise of the renewal option is at the Company's discretion. The operating lease liability includes lease payments related to options to extend or renew the lease term if the Company is reasonably certain of exercising those options. The Company, in determining the present value of lease payments, uses the Company’s incremental secured borrowing rate commensurate with the term of the underlying lease. Lease expense is primarily included in general and administrative expenses in the condensed consolidated statements of operations. Additional information regarding the Company's operating leases is as follows: (in thousands) Three months ended September 30, 2020 Three months ended September 30, 2019 Nine months ended September 30, 2020 Nine months ended September 30, 2019 Operating leases $ 662 $ 591 $ 1,916 $ 1,849 Short-term leases (1) 6 5 182 52 Total lease expense $ 668 $ 596 $ 2,098 $ 1,901 (1) Leases with an initial term of twelve months or less are not recorded on the balance sheet. Other information on operating leases Nine months ended September 30, 2020 Nine months ended September 30, 2019 Cash payments included in operating cash flows $ 1,645 $ 1,625 Right-of-use assets obtained in exchange for new lease $ 769 $ 376 Weighted average discount rate 9.11 % 9.33 % Weighted average remaining lease term in years 5.09 5.53 The following table presents the contractual maturities of the Company's lease liabilities as of September 30, 2020: (in thousands) Lease Liability Remainder of 2020 $ 485 2021 1,784 2022 1,496 2023 1,228 2024 and thereafter 2,290 Total undiscounted lease payments 7,283 Less: present value adjustment 1,450 Operating lease liability $ 5,833 The following table presents the contractual maturities of the Company's lease liabilities as of December 31, 2019: (in thousands) Future lease Payments 2020 $ 1,939 2021 1,670 2022 1,509 2023 1,294 2024 and thereafter 2,380 Total undiscounted lease payments 8,792 Less: present value adjustment 1,960 Operating lease liability $ 6,832

Other Noncurrent Liabilities

Other Noncurrent Liabilities	9 Months Ended
	Sep. 30, 2020
Liabilities, Other than Long-term Debt, Noncurrent [Abstract]
Other Noncurrent Liabilities	Other Noncurrent Liabilities The Company’s other noncurrent liabilities at September 30, 2020 and December 31, 2019 consisted of the following: (in thousands) September 30, 2020 December 31, 2019 Lease liability $ 4,465 $ 5,339 Other (1) 1,524 1,907 Total other noncurrent liabilities $ 5,989 $ 7,246

Severance

Severance	9 Months Ended
	Sep. 30, 2020
Compensation Related Costs [Abstract]
Severance	SeveranceSeverance expense was $0.4 million and $0.3 million for the three months ended September 30, 2020 and 2019, respectively, and $0.5 million and $1.0 million for the nine months ended September 30, 2020 and 2019, respectively. These amounts, which do not include stock compensation expense, were recorded in selling, general and administrative expense in the condensed consolidated statements of operations. As of September 30, 2020 and December 31, 2019, the Company had a $0.2 million and $0.4 million severance liability, respectively.

Series B Convertible Preferred

Series B Convertible Preferred Stock and Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
Series B Convertible Preferred Stock and Stockholders' Equity	Series B Convertible Preferred Stock and Stockholders’ Equity Series B Convertible Preferred Stock On June 13, 2020, the Company entered into an Investment Agreement (the “Investment Agreement”) with the Investor, an affiliate of Paine Schwartz Partners, LLC (“PSP”), pursuant to which, subject to certain closing conditions, the Investor agreed to purchase in a private placement an aggregate of $150,000,000 of convertible preferred equity of the Company. The transaction closed on July 27, 2020 and a total of 150,000 shares of the Company’s newly-designated Series B-1 Convertible Preferred Stock, par value $0.0001 per share (the “Series B-1 Preferred Stock”) were purchased in such transaction (the “Private Placement”). On September 22, 2020, following the approval of the transactions contemplated by the Investment Agreement by the necessary regulatory body, the Company issued to the Investor, for no additional consideration, a total of 150,000 shares of the Company’s newly-designated Series B-2 Convertible Preferred Stock, par value $0.0001 per share (the “Series B-2 Preferred Stock”). On September 25, 2020 (the "Exchange Date"), the Investor elected to exchange the shares of the Company’s Series B-1 Convertible Preferred Stock and Series B-2 Preferred Stock held by it for a total of 150,000 shares of the Company’s newly-designated Series B Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”). Accordingly, effective as of the Exchange Date, the Company issued 150,000 shares of Series B Convertible Preferred Stock, par value $0.0001 per share, to the Investor and all of the shares of Series B-1 Preferred Stock and Series B-2 Preferred Stock held by the Investor were cancelled. No shares of Series B-1 Preferred Stock or Series B-2 Preferred Stock are outstanding as of September 30, 2020. The Series B Preferred Stock ranks senior to the shares of the Company’s common stock with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. The Series B Preferred Stock has a liquidation preference of $1,000 per share (the “Stated Value”). Holders of the Series B Preferred Stock are entitled to a cumulative dividend at a rate of 16% per annum, of which 50% will be payable in cash and 50% will be payable in kind until the first anniversary of the Closing Date, after which 50% will be payable in cash, 37.5% will be payable in kind, and the remaining 12.5% will be payable in cash or in kind, at the Company’s option, subject in each case to adjustment under certain circumstances. Dividends on the Series B Preferred Stock are cumulative and payable quarterly in arrears. All dividends that are paid in kind will accrete to, and increase, the Stated Value. The applicable dividend rate is subject to increase by 2% per annum during any period that the Company is in breach of certain provisions of the applicable Certificate of Designation of the Preferred Stock. The Series B Preferred Stock has been classified as temporary equity as it may be contingently redeemable in the event of a change of control, which is outside of the Company's control. Associated with the Series B Preferred Stock, the Company paid $4.4 million of total dividends, of which $2.2 million were in additional preferred shares and $2.2 million were in cash for the three and nine months ended September 30, 2020, respectively. For the three and nine months ended September 30, 2019, the Company paid no dividends. As of September 30, 2020 and December 31, 2019, the Company had no accrued dividends. The Series B Preferred Stock is convertible into Common Stock at the election of the holder at any time at an initial conversion price of $5.00 (the “Conversion Price”). The Conversion Price is subject to customary adjustments, including for stock splits and other reorganizations affecting the Common Stock and pursuant to certain anti-dilution provisions for below market issuances. As of September 30, 2020 and December 31, 2019, the maximum number of shares of common stock that could be issued upon conversion of the outstanding shares of Series B Preferred Stock was 30,440,000 and 0 shares, respectively. The below table outlines the change in Series B Preferred Stock during the nine months ended September 30, 2020. Series B-1 Convertible Preferred Stock Series B-2 Convertible Preferred Stock Series B Convertible Preferred Stock (in thousands, except share) Shares Amount Shares Amount Shares Amount Balance at December 31, 2019 — $ — — $ — — $ — Issuance of preferred stock 150,000 150,000 150,000 — 150,000 150,000 Exchange to Series B preferred stock (150,000) (150,000) (150,000) — — — Issuance-related expenses — — — — — (11,516) Additional preferred shares — — — — — 2,200 Balance at September 30, 2020 — $ — — $ — 150,000 $ 140,684 In connection with the consummation of the Investment Agreement, the Company and the Investor entered into a Registration Rights Agreement (the “Registration Rights Agreement”), dated as of July 27, 2020. The Registration Rights Agreement provides that the Company will use its commercially reasonable efforts to prepare and file a shelf registration statement with the SEC no later than the first business day following January 27, 2022, and to use its commercially reasonable efforts to cause such shelf registration statement to be declared effective as promptly as is reasonably practicable after its filing to permit the public resale of registrable securities covered by the Registration Rights Agreement. The registrable securities generally include any shares of the Company’s common stock into which the Series B Preferred Stock is convertible, and any other securities issued or issuable with respect to any such shares of common stock by way of share split, share dividend, distribution, recapitalization, merger, exchange, replacement or similar event or otherwise. Common Stock The authorized common stock of the Company consists of 400,000,000 shares with a par value of $0.0001 per share. Holders of the Company’s common stock are entitled to one vote for each share of common stock. As of September 30, 2020, there were 52,393,579 shares of common stock outstanding. Warrants On July 31, 2020, all outstanding warrants, consisting of warrants to purchase 15,983,072 shares of the Company’s common stock outstanding at a strike price of $11.50, expired. Of the 15,983,072 warrants, 9,823,072 were issued as part of the units sold in the Company's initial public offering in February 2014 (1,201,928 warrants were subsequently repurchased during 2015) and 6,160,000 warrants were sold in a private placement at the time of such public offering. Series A Preferred Stock In connection with and as a condition to the consummation of the Business Combination, the Company issued R&H one share of Series A Preferred Stock. R&H, voting as a separate class, is entitled to appoint one director to the Company’s board of directors for so long as R&H beneficially holds 10% or more of the aggregate amount of the outstanding shares of common stock and non-voting common stock of the Company. The Series A Preferred Stock has no other rights. ATM Facility In December 2018, the Company filed a shelf registration statement (File No. 333-229002) (the “Form S-3 Shelf”) with the Securities and Exchange Commission, that became effective in February 2019. On June 25, 2020, the Company established an at-the-market offering facility (the “ATM Facility”) under the Form S-3 Shelf, with Virtu Americas LLC, acting as sales agent with support from H.C. Wainwright & Co and Roth Capital Partners. The Company’s board of directors approved sales of up to $30,000,000 maximum aggregate offering of the Company’s common stock under the ATM Facility. Effective as of August 7, 2020, the Company suspended sales under its ATM Facility, in light of the Company’s recent completion of the Refinancing and current market conditions. No sales have been effected pursuant to the ATM Facility to date.

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock-based Compensation	Stock-based CompensationIn July 2015, the Company adopted the 2015 Incentive Compensation Plan (as amended, the “Plan”), pursuant to which the Compensation Committee of the Company is authorized to grant up to 7,150,000 shares to officers and employees of the Company, in the form of equity-based awards, including time or performance based options and restricted stock. In June 2019, the Company's shareholders approved the 2019 Employee Stock Purchase Plan (the "ESPP"), which became effective July 1, 2019. 500,000 shares of common stock are reserved for issuance under the ESPP. As of September 30, 2020, 253,042 shares had been issued under the ESPP. Stock compensation expense for equity-classified and liability-classified awards was $0.9 million and $1.0 million for the three months ended September 30, 2020 and 2019, respectively. Stock compensation expense for equity-classified and liability-classified awards was $2.7 million and $2.1 million for the nine months ended September 30, 2020 and 2019, respectively. Stock compensation expense is recognized in cost of goods sold, selling, general and administrative expenses and research and development expenses. At September 30, 2020, there was $5.3 million of unrecognized compensation cost relating to outstanding unvested equity instruments expected to be recognized over the weighted average period of 1.9 years.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic (loss) income per share is calculated by dividing net (loss) income by the weighted average number of common shares outstanding for the period. The Company had a loss for the nine months ended September 30, 2020 and 2019. Therefore, the effect of stock-based awards including options, restricted stock, restricted stock units and warrants outstanding at September 30, 2020 and 2019, respectively, have not been included in the computation of diluted loss per share because their inclusion would have been anti-dilutive. The following is a reconciliation of the weighted-average common shares outstanding used for the computation of basic and diluted net (loss) income per common share: Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended Basic weighted-average common shares outstanding 51,001,852 50,227,590 50,765,829 50,138,835 Effect of dilutive options, performance stock units and restricted stock — 60,714 — — Diluted weighted-average shares outstanding 51,001,852 50,288,304 50,765,829 50,138,835 Securities that could potentially be dilutive are excluded from the computation of diluted (loss) income per share when a loss from continuing operations exists, when the exercise price exceeds the average closing price of the Company's common stock during the period, or for contingently issued shares, if the contingency is not met at the end of the reporting period, because their inclusion would result in an anti-dilutive effect on per share amounts. The following represents the weighted-average number of shares that could potentially dilute basic earnings per share in the future: Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended Convertible preferred stock 21,526,522 — 7,227,883 — Stock-based compensation awards (1) : Stock options 799,570 1,028,583 804,267 949,987 Restricted stock to non-directors 1,811,016 749,510 1,079,151 624,930 Warrants: Private placement warrants 2,075,652 6,160,000 4,788,613 6,160,000 Public warrants 3,309,948 9,823,072 7,636,184 9,823,072 (1) SARs and Phantom Shares are payable in cash so will have no impact on number of shares. Warrants and options are considered anti-dilutive and excluded when the exercise price exceeds the average market value of the Company’s common stock price during the applicable period.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesThe provision for income taxes consists of provisions for federal, state and foreign incomes taxes. The effective tax rates for the periods ended September 30, 2020 and September 30, 2019, reflect the Company’s expected tax rate on reported income (loss) from continuing operations before income tax and tax adjustments. The Company operates in a global environment with significant operations in the U.S. and various other jurisdictions outside the U.S. Accordingly, the consolidated income tax rate is a composite rate reflecting the Company’s earnings and the applicable tax rates in the various jurisdictions where the Company operates. On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act. The CARES Act includes tax changes and financial aid designed to protect the American people from the public health and economic impacts of COVID-19. The tax changes include allowing net operating losses to be carried back five years, suspending the 80% of taxable limitation on the use of net operating losses, an increase of the 30% of EBITDA limitation on the deduction of interest expense to 50%, and acceleration of the refund for alternative minimum tax credits granted under the 2017 Tax Cuts and Jobs Act (“TCJA”). Most significant to the Company are the modifications on the limitation of business interest deductions for tax years beginning in 2019 and 2020. The modifications to Section 163(j) increase the allowable business interest deduction from 30% to 50% of adjusted taxable income. The Company's U.S. operations have incurred cumulative taxable losses through September 30, 2020. The Company’s U.S. net operating loss carry forwards and carry forwards of other tax attributes are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. The utilization of the tax attributes may become restricted in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, as well as similar state tax provisions. This could limit the amount of the tax attributes that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will generally be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. Please refer to Note 4 regarding the ownership change in the quarter ended September 30, 2020. The Company completed a Section 382 study and determined the ownership change gave rise to the restrictions that will limit the realizability of certain U.S. tax attributes. Typically, the Company has calculated its provision for income taxes during its interim reporting periods by applying an estimate of the annual effective tax rate for the full year "ordinary" income or loss for the respective reporting period. For the nine months ended September 30, 2020, the Company has computed its provision for income taxes under the discrete method which allows the Company to calculate its tax provision based upon the actual effective tax rate for the year-to-date. The discrete method was determined to be an appropriate method for estimating its tax provision for the nine months ended September 30, 2020 as it provides a reliable estimate as opposed to changes in estimated "ordinary" income or loss which would have resulted in significant fluctuations when estimating the annual effective tax rate. The effective tax rate for the nine months ended September 30, 2020 differs from the U.S. statutory tax rate of 21%, primarily because of changes in valuation allowance positions related to the United States and certain foreign jurisdictions and by foreign exchange currency gains, offset by foreign provision to return tax benefits, primarily in France. The Company recorded an increase of $24.7 million in the valuation allowance for the three months ended September 30, 2020, primarily as a result of the ownership change that will limit the realizability of certain U.S. tax attributes. The Company's effective tax rate for the three and nine months ended September 30, 2020 was 743.9% and (111.7)%, respectively, compared to the effective tax rate for the three and nine months ended September 30, 2019 of 214.0% and 28.2%, respectively.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Segment Information	Segment Information The authoritative guidance for disclosures about segments of an enterprise establishes standards for reporting information about segments. It defines operating segments as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. We currently operate and manage our business as two operating segments. Our chief operating decision-makers allocate resources and assess performance of the business for each segment. Accordingly, we consider ourselves to have two operating and reportable segments (i) AgroFresh core and (ii) Tecnidex. AgroFresh core business is providing produce preservation and waste prevention solutions for growers and packers. Its products include SmartFresh, Harvista, RipeLock and FreshCloud. Tecnidex is a provider of fungicides, disinfectants, waxes and coatings primarily focused on the citrus market. Our chief operating decision-maker does not evaluate operating segments using asset or liability information. The following table presents a breakdown of our revenues and gross profit based on reportable segments for the three and nine months ended September 30, 2020 and 2019. (in thousands) Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended AgroFresh Core Revenues $ 49,343 $ 45,917 $ 94,723 $ 96,272 Gross Profit 38,283 34,182 73,080 72,679 Tecnidex Revenues 3,427 3,055 11,052 12,823 Gross Profit 976 898 4,203 4,900 Total Revenues $ 52,770 $ 48,972 $ 105,775 $ 109,095 Total Gross Profit $ 39,259 $ 35,080 $ 77,283 $ 77,579

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company is currently involved in various claims and legal actions that arise in the ordinary course of business. The Company has recorded reserves for loss contingencies based on the specific circumstances of each case. Such reserves are recorded when it is probable that a loss has been incurred as of the balance sheet date and can be reasonably estimated. Although the results of litigation and claims can never be predicted with certainty, the Company does not believe that the ultimate resolution of these actions will have a material adverse effect on the Company’s business, financial condition or results of operations. On October 14, 2019, the Company was awarded a verdict of $31.1 million in damages, related to, among other things, trade secret misappropriation and willful patent infringement, in its litigation against Decco Post-Harvest, Inc. ("Decco") and Decco's parent company, UPL Limited. The award is subject to post-verdict review by the Court and any appeals that may be taken by the parties in the future. In July 2020, three separate putative class action lawsuits were filed against the Company, each alleging that the Company’s disclosures regarding the transactions contemplated by the Investment Agreement contained in its proxy statement for the 2020 annual meeting of the Company’s stockholders were inadequate. Purchase Commitments The Company has various purchasing contracts for contract manufacturing and research and development services which are based on the requirements of the business. Generally, the contracts are at prices not in excess of current market prices and do not commit the business to obligations outside the normal customary terms for similar contracts.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Liabilities Measured at Fair Value on a Recurring Basis The following table presents the fair value of the Company’s financial instruments that are measured at fair value on a recurring basis as of September 30, 2020: (in thousands) Level 1 Level 2 Level 3 Total Liability-classified stock compensation (1) $ — $ — $ 294 $ 294 Interest rate swap — — 290 290 Total $ — $ — $ 584 $ 584 The following table presents the fair value of the Company’s financial instruments that are measured at fair value on a recurring basis as of December 31, 2019: (in thousands) Level 1 Level 2 Level 3 Total Liability-classified stock compensation (1) $ — $ — $ 218 $ 218 Interest rate swap — — (95) (95) Total $ — $ — $ 123 $ 123 (1) The fair values of phantom stock units were estimated using a Monte Carlo simulation pricing model with the assumptions described below: September 30, 2020 Grant date fair value $ 1.70 — $7.28 Risk-free interest rate 0.27 % — 2.39% Expected life (years) 2.71 — 2.75 Estimated volatility factor 65.1 % — 69.9% Expected dividends None There were no transfers between Level 1 and Level 2 and no transfers out of Level 3 of the fair value hierarchy during the nine months ended September 30, 2020. At September 30, 2020, the Company evaluated the amount recorded under the Restated Term Loan and determined that the fair value was approximately $267.4 million. The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value. Changes in Financial Instruments Measured at Level 3 Fair Value on a Recurring Basis The following table presents the changes during the period presented in the Company's Level 3 financial instrument liabilities that are measured at fair value on a recurring basis. (in thousands) Liability-classified stock compensation Interest rate swap Total Balance, December 31, 2019 $ 218 $ (95) $ 123 Stock compensation activity 76 — 76 Mark-to-market adjustment — 385 385 Balance, September 30, 2020 $ 294 $ 290 $ 584

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policy)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission. These financial statements include all adjustments that are necessary for a fair presentation of the Company's condensed consolidated results of operations, financial condition and cash flows for the periods shown, including normal, recurring accruals and other items. The condensed consolidated results of operations for the interim periods presented are not necessarily indicative of results for the full year. For additional information, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report filed on Form 10-K for the year ended December 31, 2019.
Revenue Recognition	Adoption of Highly Inflationary Accounting in Argentina GAAP requires the use of highly inflationary accounting for countries whose cumulative three-year inflation rate exceeds 100 percent. The Company closely monitors the inflation data and currency volatility in Argentina, where there are multiple data sources for measuring and reporting inflation. In the second quarter of 2018, the Argentine peso rapidly devalued relative to the U.S. dollar, which along with increased inflation, indicated that the three-year cumulative inflation rate in that country exceeded 100 percent as of June 30, 2018. As a result, the Company adopted highly inflationary accounting as of July 1, 2018 for its subsidiary in Argentina. Under highly inflationary accounting, the functional currency of the Company's subsidiary in Argentina became the U.S. dollar, and its income statement and balance sheet are measured in U.S. dollars using both current and historical rates of exchange. The effect of changes in exchange rates on Argentine peso-denominated monetary assets and liabilities are reflected in earnings. As the three-year cumulative inflation rate exceeded 100 percent as of September 30, 2020, there is no change to highly inflationary accounting. As of September 30, 2020, the Company’s subsidiary in Argentina had a net asset position of $3.0 million. Net sales attributable to Argentina were approximately 6% and 6% of the Company’s consolidated net sales for each of the nine months ended September 30, 2020 and 2019, respectively. Disaggregation of Revenue The Company disaggregates revenue from contracts with customers into geographic region, product and timing of transfer of goods and services. The Company determined that disaggregating revenue into these categories achieves the disclosure objective of depicting how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. Revenues for the three months ended September 30, 2020 (in thousands) Region North America EMEA Latin America Asia Pacific (4) Total Revenues Product 1-MCP based $ 17,122 $ 28,906 $ 845 $ 1,165 $ 48,038 Fungicides, waxes, coatings and disinfectants 534 3,011 575 — 4,120 Other* 190 115 210 97 612 $ 17,846 $ 32,032 $ 1,630 $ 1,262 $ 52,770 Pattern of Revenue Recognition Products transferred at a point in time $ 17,663 $ 31,921 $ 1,420 $ 1,165 $ 52,169 Services transferred over time 183 111 210 97 601 $ 17,846 $ 32,032 $ 1,630 $ 1,262 $ 52,770 Revenues for the three months ended September 30, 2019 (in thousands) Region North America EMEA Latin America Asia Pacific (4) Total Revenues Product 1-MCP based $ 19,726 $ 22,377 $ 1,680 $ 1,605 $ 45,388 Fungicides, waxes, coatings and disinfectants — 2,857 198 — 3,055 Other* 218 86 108 117 529 $ 19,944 $ 25,320 $ 1,986 $ 1,722 $ 48,972 Pattern of Revenue Recognition Products transferred at a point in time $ 19,802 $ 25,238 $ 1,877 $ 1,605 $ 48,522 Services transferred over time 142 82 109 117 450 $ 19,944 $ 25,320 $ 1,986 $ 1,722 $ 48,972 Revenues for the nine months ended September 30, 2020 (in thousands) Region North America EMEA Latin America Asia Pacific (4) Total Revenues Product 1-MCP based $ 19,264 $ 37,223 $ 23,217 $ 11,538 $ 91,242 Fungicides, waxes, coatings and disinfectants 534 9,650 1,750 — 11,934 Other* 722 700 938 239 2,599 $ 20,520 $ 47,573 $ 25,905 $ 11,777 $ 105,775 Pattern of Revenue Recognition Products transferred at a point in time $ 19,823 $ 46,887 $ 25,338 $ 11,538 $ 103,586 Services transferred over time 697 686 567 239 2,189 $ 20,520 $ 47,573 $ 25,905 $ 11,777 $ 105,775 Revenues for the nine months ended September 30, 2019 (in thousands) Region North America EMEA Latin America Asia Pacific (4) Total Revenues Product 1-MCP based $ 23,084 $ 31,965 $ 27,503 $ 11,287 $ 93,839 Fungicides, waxes, coatings and disinfectants — 11,365 1,458 — 12,823 Other* 954 927 381 171 2,433 $ 24,038 $ 44,257 $ 29,342 $ 11,458 $ 109,095 Pattern of Revenue Recognition Products transferred at a point in time $ 23,380 $ 43,374 $ 29,159 $ 11,309 $ 107,222 Services transferred over time 658 883 183 149 1,873 $ 24,038 $ 44,257 $ 29,342 $ 11,458 $ 109,095 *Other includes FreshCloud, technical services and sales-type leases related to Tecnidex. ——————————————————————————————————— (1) North America includes the United States and Canada. (2) EMEA includes Europe, the Middle East and Africa. (3) Latin America includes Argentina, Brazil, Chile, Costa Rica, Colombia, Dominican Republic, Ecuador, Guatemala, Mexico, Peru and Uruguay. (4) Asia Pacific includes Australia, China, India, Japan, New Zealand, the Philippines, South Korea, Taiwan and Thailand. Contract Assets and Liabilities ASC 606 requires an entity to present a revenue contract as a contract asset when the entity performs its obligations under the contract by transferring goods or services to a customer before the customer pays consideration or before payment is due. ASC 606 also requires an entity to present a revenue contract as a contract liability in instances when a customer pays consideration, or an entity has a right to an amount of consideration that is unconditional (e.g., receivable), before the entity transfers a good or service to the customer. The following table presents changes in the Company’s contract assets and liabilities during the nine months ended September 30, 2020 and the year ended December 31, 2019: (in thousands) Balance at Additions Deductions Balance at Contract assets: Unbilled revenue $ 1,666 11,670 (9,423) $ 3,913 Contract liabilities: Deferred revenue $ 1,175 4,437 (4,239) $ 1,373 (in thousands) Balance at Additions Deductions Balance at Contract assets: Unbilled revenue $ 1,956 10,029 (10,319) $ 1,666 Contract liabilities: Deferred revenue $ 1,280 3,032 (3,137) $ 1,175
Recently Issued Accounting Standards and Pronouncements	Recently Issued Accounting Standards and Pronouncements In January 2017, the Financial Accounting Standards Board ("FASB") issued ASU No. 2017-04, "Intangibles - Goodwill and Other", which simplifies the test for goodwill impairment. The guidance was effective for the Company beginning in the first quarter of fiscal year 2020. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the condensed consolidated financial statements of the Company. In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments”, which introduces a new current expense credit loss model to measure impairment on certain types of financial instruments. This update requires an entity to use a forward-looking expected credit loss model for accounts receivable, loans, and other financial instruments. In addition, the FASB issued various amendments during 2018 and 2019 to clarify the provisions of ASU 2016-13. The standard was effective for fiscal years beginning January 1, 2020, including interim periods. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the financial statements of the Company. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify and add certain disclosure requirements related to fair value measurements covered in Topic 820. The new standard was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the notes to condensed consolidated financial statements of the Company. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments simplify the accounting for income taxes by removing certain exceptions to the general principles of Topic 740, "Income Taxes" and also improve consistent application by clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted, with the amendments to be applied on a retrospective, modified retrospective or prospective basis, depending on the specific amendment. The Company is currently evaluating the impact of adopting this guidance. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments are intended to ease the potential burden in accounting for, or recognizing the effects of, reference rate

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Schedule of disaggregated revenue	Revenues for the three months ended September 30, 2020 (in thousands) Region North America EMEA Latin America Asia Pacific (4) Total Revenues Product 1-MCP based $ 17,122 $ 28,906 $ 845 $ 1,165 $ 48,038 Fungicides, waxes, coatings and disinfectants 534 3,011 575 — 4,120 Other* 190 115 210 97 612 $ 17,846 $ 32,032 $ 1,630 $ 1,262 $ 52,770 Pattern of Revenue Recognition Products transferred at a point in time $ 17,663 $ 31,921 $ 1,420 $ 1,165 $ 52,169 Services transferred over time 183 111 210 97 601 $ 17,846 $ 32,032 $ 1,630 $ 1,262 $ 52,770 Revenues for the three months ended September 30, 2019 (in thousands) Region North America EMEA Latin America Asia Pacific (4) Total Revenues Product 1-MCP based $ 19,726 $ 22,377 $ 1,680 $ 1,605 $ 45,388 Fungicides, waxes, coatings and disinfectants — 2,857 198 — 3,055 Other* 218 86 108 117 529 $ 19,944 $ 25,320 $ 1,986 $ 1,722 $ 48,972 Pattern of Revenue Recognition Products transferred at a point in time $ 19,802 $ 25,238 $ 1,877 $ 1,605 $ 48,522 Services transferred over time 142 82 109 117 450 $ 19,944 $ 25,320 $ 1,986 $ 1,722 $ 48,972 Revenues for the nine months ended September 30, 2020 (in thousands) Region North America EMEA Latin America Asia Pacific (4) Total Revenues Product 1-MCP based $ 19,264 $ 37,223 $ 23,217 $ 11,538 $ 91,242 Fungicides, waxes, coatings and disinfectants 534 9,650 1,750 — 11,934 Other* 722 700 938 239 2,599 $ 20,520 $ 47,573 $ 25,905 $ 11,777 $ 105,775 Pattern of Revenue Recognition Products transferred at a point in time $ 19,823 $ 46,887 $ 25,338 $ 11,538 $ 103,586 Services transferred over time 697 686 567 239 2,189 $ 20,520 $ 47,573 $ 25,905 $ 11,777 $ 105,775 Revenues for the nine months ended September 30, 2019 (in thousands) Region North America EMEA Latin America Asia Pacific (4) Total Revenues Product 1-MCP based $ 23,084 $ 31,965 $ 27,503 $ 11,287 $ 93,839 Fungicides, waxes, coatings and disinfectants — 11,365 1,458 — 12,823 Other* 954 927 381 171 2,433 $ 24,038 $ 44,257 $ 29,342 $ 11,458 $ 109,095 Pattern of Revenue Recognition Products transferred at a point in time $ 23,380 $ 43,374 $ 29,159 $ 11,309 $ 107,222 Services transferred over time 658 883 183 149 1,873 $ 24,038 $ 44,257 $ 29,342 $ 11,458 $ 109,095 *Other includes FreshCloud, technical services and sales-type leases related to Tecnidex. ——————————————————————————————————— (1) North America includes the United States and Canada. (2) EMEA includes Europe, the Middle East and Africa. (3) Latin America includes Argentina, Brazil, Chile, Costa Rica, Colombia, Dominican Republic, Ecuador, Guatemala, Mexico, Peru and Uruguay. (4) Asia Pacific includes Australia, China, India, Japan, New Zealand, the Philippines, South Korea, Taiwan and Thailand.
Schedule of changes in contract assets and liabilities	The following table presents changes in the Company’s contract assets and liabilities during the nine months ended September 30, 2020 and the year ended December 31, 2019: (in thousands) Balance at Additions Deductions Balance at Contract assets: Unbilled revenue $ 1,666 11,670 (9,423) $ 3,913 Contract liabilities: Deferred revenue $ 1,175 4,437 (4,239) $ 1,373 (in thousands) Balance at Additions Deductions Balance at Contract assets: Unbilled revenue $ 1,956 10,029 (10,319) $ 1,666 Contract liabilities: Deferred revenue $ 1,280 3,032 (3,137) $ 1,175

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Schedule of inventories	Inventories at September 30, 2020 and December 31, 2019 consisted of the following: (in thousands) September 30, 2020 December 31, 2019 Raw material $ 3,026 $ 3,401 Work-in-process 8,575 7,278 Finished goods 11,619 10,974 Supplies 1,224 968 Total inventories $ 24,444 $ 22,621

Other Current Assets (Tables)

Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of other current assets	The Company's other current assets at September 30, 2020 and December 31, 2019 consisted of the following: (in thousands) September 30, 2020 December 31, 2019 VAT receivable $ 7,627 $ 4,925 Prepaid income tax asset 5,349 3,616 Prepaid and other current assets 4,289 3,261 Total other current assets $ 17,265 $ 11,802

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Property and equipment at September 30, 2020 and December 31, 2019 consisted of the following: (in thousands, except for useful life data) Useful life September 30, 2020 December 31, 2019 Buildings and leasehold improvements 7-20 $ 7,032 $ 6,508 Machinery & equipment 1-12 11,953 10,954 Furniture 1-12 2,944 2,681 Construction in progress 1,149 902 23,078 21,045 Less: accumulated depreciation (9,803) (7,868) Total property and equipment, net $ 13,275 $ 13,177

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of changes in the carrying amount of goodwill	Changes in the carrying amount of goodwill for the nine months ended September 30, 2020 and the year ended December 31, 2019 were as follows: (in thousands) September 30, 2020 December 31, 2019 Beginning balance $ 6,323 $ 6,670 Foreign currency translation 282 (347) Ending balance $ 6,605 $ 6,323
Schedule of other intangible assets	The Company’s intangible assets at September 30, 2020 and December 31, 2019 consisted of the following: September 30, 2020 December 31, 2019 (in thousands) Gross Carrying Accumulated Impairment Net Gross Carrying Accumulated Impairment Net Other intangible assets: Developed technology $ 798,240 $ (244,918) $ — $ 553,322 $ 758,760 $ (206,998) $ — $ 551,762 In-process research and development — — — — 39,000 (7,222) — 31,778 Trade name 27,158 — — 27,158 27,200 — 27,200 Service provider network 2,000 — — 2,000 2,000 — — 2,000 Customer relationships 18,551 (3,548) — 15,003 18,058 (2,993) — 15,065 Software 10,691 (8,967) — 1,724 9,861 (5,347) (992) 3,522 Other 100 (71) — 29 100 (58) — 42 Total intangible assets $ 856,740 $ (257,504) $ — $ 599,236 $ 854,979 $ (222,618) $ (992) $ 631,369
Schedule of estimated annual amortization expense for finite-lived intangible assets	Estimated annual amortization expense for finite-lived intangible assets subsequent to September 30, 2020 is as follows: (in thousands) Amount 2020 (remaining) $ 12,045 2021 41,730 2022 40,893 2023 40,791 2024 40,791 Thereafter 393,828 Total $ 570,078

Other Assets (Tables)

Other Assets (Tables)	9 Months Ended
	Sep. 30, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets	The Company’s other assets at September 30, 2020 and December 31, 2019 consisted of the following: (in thousands) September 30, 2020 December 31, 2019 Right-of-use asset $ 5,657 $ 6,599 Long term sales-type lease receivable 2,354 2,501 Other long term receivable 3,438 3,061 Total other assets $ 11,449 $ 12,161

Accrued and Other Current Lia_2

Accrued and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Accrued and other current liabilities	The Company’s accrued and other current liabilities at September 30, 2020 and December 31, 2019 consisted of the following: (in thousands) September 30, 2020 December 31, 2019 Accrued compensation and benefits $ 7,111 $ 7,307 Accrued taxes 6,501 3,017 Lease liability 1,368 1,493 Accrued rebates payable 3,001 1,377 Insurance premium financing payable 1,151 1,000 Severance 218 444 Deferred revenue 1,373 1,175 Accrued interest 66 71 Interest rate swap 290 — Other 5,586 8,466 Total accrued and other current liabilities $ 26,665 $ 24,350

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of debt, net of unamortized discount and deferred financing fees	The Company’s debt, net of unamortized deferred issuance costs, at September 30, 2020 and December 31, 2019 consisted of the following: (in thousands) September 30, 2020 December 31, 2019 Total term loan outstanding $ 275,000 $ 405,875 Unamortized deferred issuance costs (9,018) (3,886) Tecnidex loan outstanding 2,184 750 Less: Amounts due within one year 3,316 4,675 Total long-term debt due after one year $ 264,850 $ 398,064
Schedule of principal repayments under the term loan	Scheduled principal repayments of debt subsequent to September 30, 2020 are as follows: (in thousands) Amount 2020 (remaining) $ 815 2021 3,348 2022 3,390 2023 3,181 2024 and thereafter $ 266,450 Total $ 277,184

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Schedule of Additional Information of Operating Leases	Additional information regarding the Company's operating leases is as follows: (in thousands) Three months ended September 30, 2020 Three months ended September 30, 2019 Nine months ended September 30, 2020 Nine months ended September 30, 2019 Operating leases $ 662 $ 591 $ 1,916 $ 1,849 Short-term leases (1) 6 5 182 52 Total lease expense $ 668 $ 596 $ 2,098 $ 1,901 (1) Leases with an initial term of twelve months or less are not recorded on the balance sheet. Other information on operating leases Nine months ended September 30, 2020 Nine months ended September 30, 2019 Cash payments included in operating cash flows $ 1,645 $ 1,625 Right-of-use assets obtained in exchange for new lease $ 769 $ 376 Weighted average discount rate 9.11 % 9.33 % Weighted average remaining lease term in years 5.09 5.53
Schedule of Maturities of Lease Liabilities	The following table presents the contractual maturities of the Company's lease liabilities as of September 30, 2020: (in thousands) Lease Liability Remainder of 2020 $ 485 2021 1,784 2022 1,496 2023 1,228 2024 and thereafter 2,290 Total undiscounted lease payments 7,283 Less: present value adjustment 1,450 Operating lease liability $ 5,833 The following table presents the contractual maturities of the Company's lease liabilities as of December 31, 2019: (in thousands) Future lease Payments 2020 $ 1,939 2021 1,670 2022 1,509 2023 1,294 2024 and thereafter 2,380 Total undiscounted lease payments 8,792 Less: present value adjustment 1,960 Operating lease liability $ 6,832

Other Noncurrent Liabilities (T

Other Noncurrent Liabilities (Tables)	9 Months Ended
	Sep. 30, 2020
Liabilities, Other than Long-term Debt, Noncurrent [Abstract]
Other noncurrent liabilities	The Company’s other noncurrent liabilities at September 30, 2020 and December 31, 2019 consisted of the following: (in thousands) September 30, 2020 December 31, 2019 Lease liability $ 4,465 $ 5,339 Other (1) 1,524 1,907 Total other noncurrent liabilities $ 5,989 $ 7,246

Series B Convertible Preferre_2

Series B Convertible Preferred Stock and Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Change in Series B Preferred Stock	The below table outlines the change in Series B Preferred Stock during the nine months ended September 30, 2020. Series B-1 Convertible Preferred Stock Series B-2 Convertible Preferred Stock Series B Convertible Preferred Stock (in thousands, except share) Shares Amount Shares Amount Shares Amount Balance at December 31, 2019 — $ — — $ — — $ — Issuance of preferred stock 150,000 150,000 150,000 — 150,000 150,000 Exchange to Series B preferred stock (150,000) (150,000) (150,000) — — — Issuance-related expenses — — — — — (11,516) Additional preferred shares — — — — — 2,200 Balance at September 30, 2020 — $ — — $ — 150,000 $ 140,684

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Schedule of weighted average common shares outstanding	The following is a reconciliation of the weighted-average common shares outstanding used for the computation of basic and diluted net (loss) income per common share: Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended Basic weighted-average common shares outstanding 51,001,852 50,227,590 50,765,829 50,138,835 Effect of dilutive options, performance stock units and restricted stock — 60,714 — — Diluted weighted-average shares outstanding 51,001,852 50,288,304 50,765,829 50,138,835
Amounts that could potentially dilute basic earnings per share	The following represents the weighted-average number of shares that could potentially dilute basic earnings per share in the future: Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended Convertible preferred stock 21,526,522 — 7,227,883 — Stock-based compensation awards (1) : Stock options 799,570 1,028,583 804,267 949,987 Restricted stock to non-directors 1,811,016 749,510 1,079,151 624,930 Warrants: Private placement warrants 2,075,652 6,160,000 4,788,613 6,160,000 Public warrants 3,309,948 9,823,072 7,636,184 9,823,072 (1) SARs and Phantom Shares are payable in cash so will have no impact on number of shares.

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Schedule of revenue by segment	The following table presents a breakdown of our revenues and gross profit based on reportable segments for the three and nine months ended September 30, 2020 and 2019. (in thousands) Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended AgroFresh Core Revenues $ 49,343 $ 45,917 $ 94,723 $ 96,272 Gross Profit 38,283 34,182 73,080 72,679 Tecnidex Revenues 3,427 3,055 11,052 12,823 Gross Profit 976 898 4,203 4,900 Total Revenues $ 52,770 $ 48,972 $ 105,775 $ 109,095 Total Gross Profit $ 39,259 $ 35,080 $ 77,283 $ 77,579

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Tabular disclosure of financial instruments measured at fair value on a recurring basis	The following table presents the fair value of the Company’s financial instruments that are measured at fair value on a recurring basis as of September 30, 2020: (in thousands) Level 1 Level 2 Level 3 Total Liability-classified stock compensation (1) $ — $ — $ 294 $ 294 Interest rate swap — — 290 290 Total $ — $ — $ 584 $ 584 The following table presents the fair value of the Company’s financial instruments that are measured at fair value on a recurring basis as of December 31, 2019: (in thousands) Level 1 Level 2 Level 3 Total Liability-classified stock compensation (1) $ — $ — $ 218 $ 218 Interest rate swap — — (95) (95) Total $ — $ — $ 123 $ 123 (1) The fair values of phantom stock units were estimated using a Monte Carlo simulation pricing model with the assumptions described below: September 30, 2020 Grant date fair value $ 1.70 — $7.28 Risk-free interest rate 0.27 % — 2.39% Expected life (years) 2.71 — 2.75 Estimated volatility factor 65.1 % — 69.9% Expected dividends None
Changes in financial instruments measured at level 3 fair value on a recurring basis	The following table presents the changes during the period presented in the Company's Level 3 financial instrument liabilities that are measured at fair value on a recurring basis. (in thousands) Liability-classified stock compensation Interest rate swap Total Balance, December 31, 2019 $ 218 $ (95) $ 123 Stock compensation activity 76 — 76 Mark-to-market adjustment — 385 385 Balance, September 30, 2020 $ 294 $ 290 $ 584

Description of Business (Detail

Description of Business (Details) storage_room in Thousands	9 Months Ended
	Sep. 30, 2020storage_roomcountry
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating countries (over) | country	50
Number of storage rooms (over) | storage_room	25

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - Argentina - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Subsidiaries
Concentration Risk [Line Items]
Net assets	$ 3
Revenue from Contract with Customer | Geographic Concentration Risk
Concentration Risk [Line Items]
Concentration risk percentage	6.00%	6.00%
Revenue Benchmark | Geographic Concentration Risk
Concentration Risk [Line Items]
Concentration risk percentage		6.00%

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Summary of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Total Revenues	$ 52,770	$ 48,972	$ 105,775	$ 109,095
North America
Disaggregation of Revenue [Line Items]
Total Revenues	17,846	19,944	20,520	24,038
EMEA
Disaggregation of Revenue [Line Items]
Total Revenues	32,032	25,320	47,573	44,257
Latin America
Disaggregation of Revenue [Line Items]
Total Revenues	1,630	1,986	25,905	29,342
Asia Pacific
Disaggregation of Revenue [Line Items]
Total Revenues	1,262	1,722	11,777	11,458
Products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total Revenues	52,169	48,522	103,586	107,222
Products transferred at a point in time | North America
Disaggregation of Revenue [Line Items]
Total Revenues	17,663	19,802	19,823	23,380
Products transferred at a point in time | EMEA
Disaggregation of Revenue [Line Items]
Total Revenues	31,921	25,238	46,887	43,374
Products transferred at a point in time | Latin America
Disaggregation of Revenue [Line Items]
Total Revenues	1,420	1,877	25,338	29,159
Products transferred at a point in time | Asia Pacific
Disaggregation of Revenue [Line Items]
Total Revenues	1,165	1,605	11,538	11,309
Services transferred over time
Disaggregation of Revenue [Line Items]
Total Revenues	601	450	2,189	1,873
Services transferred over time | North America
Disaggregation of Revenue [Line Items]
Total Revenues	183	142	697	658
Services transferred over time | EMEA
Disaggregation of Revenue [Line Items]
Total Revenues	111	82	686	883
Services transferred over time | Latin America
Disaggregation of Revenue [Line Items]
Total Revenues	210	109	567	183
Services transferred over time | Asia Pacific
Disaggregation of Revenue [Line Items]
Total Revenues	97	117	239	149
1-MCP based
Disaggregation of Revenue [Line Items]
Total Revenues	48,038	45,388	91,242	93,839
1-MCP based | North America
Disaggregation of Revenue [Line Items]
Total Revenues	17,122	19,726	19,264	23,084
1-MCP based | EMEA
Disaggregation of Revenue [Line Items]
Total Revenues	28,906	22,377	37,223	31,965
1-MCP based | Latin America
Disaggregation of Revenue [Line Items]
Total Revenues	845	1,680	23,217	27,503
1-MCP based | Asia Pacific
Disaggregation of Revenue [Line Items]
Total Revenues	1,165	1,605	11,538	11,287
Fungicides, waxes, coatings and disinfectants
Disaggregation of Revenue [Line Items]
Total Revenues	4,120	3,055	11,934	12,823
Fungicides, waxes, coatings and disinfectants | North America
Disaggregation of Revenue [Line Items]
Total Revenues	534	0	534	0
Fungicides, waxes, coatings and disinfectants | EMEA
Disaggregation of Revenue [Line Items]
Total Revenues	3,011	2,857	9,650	11,365
Fungicides, waxes, coatings and disinfectants | Latin America
Disaggregation of Revenue [Line Items]
Total Revenues	575	198	1,750	1,458
Fungicides, waxes, coatings and disinfectants | Asia Pacific
Disaggregation of Revenue [Line Items]
Total Revenues	0	0	0	0
Other
Disaggregation of Revenue [Line Items]
Total Revenues	612	529	2,599	2,433
Other | North America
Disaggregation of Revenue [Line Items]
Total Revenues	190	218	722	954
Other | EMEA
Disaggregation of Revenue [Line Items]
Total Revenues	115	86	700	927
Other | Latin America
Disaggregation of Revenue [Line Items]
Total Revenues	210	108	938	381
Other | Asia Pacific
Disaggregation of Revenue [Line Items]
Total Revenues	$ 97	$ 117	$ 239	$ 171

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies - Summary of Contract Assets and Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Contract assets:
Beginning balance	$ 1,666	$ 1,666	$ 1,956
Additions	10,029	11,670
Deductions	(10,319)	(9,423)	(10,300)
Ending balance		3,913	1,666
Contract liabilities:
Beginning balance	1,175	1,175	1,280
Additions	3,032	4,437
Deductions	$ (3,137)	(4,239)	(3,100)
Ending balance		1,373	$ 1,175
Amounts reclassified from unbilled revenue to accounts receivable		(9,400)
Amounts reclassified from deferred revenue to revenue		$ (4,200)

Business Combinations and Ass_2

Business Combinations and Asset Acquisition (Details) $ in Millions	Dec. 01, 2017USD ($)	Apr. 04, 2017	Jul. 31, 2015USD ($)shares	Dec. 31, 2019USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Sep. 30, 2020country	Nov. 07, 2017country
Class of Warrant or Right [Line Items]
Number of operating countries | country							50
Tax receivables agreement (TRA)
Class of Warrant or Right [Line Items]
Settlement of preexisting relationship, amount				$ 16
Settlement with related party, liability				27.9
Settlement with related party, deferred income taxes				$ 5.9
Tax receivables agreement (TRA) | Dow
Class of Warrant or Right [Line Items]
Rate of tax receivable agreement		50.00%
AgroFresh Inc.
Class of Warrant or Right [Line Items]
Cash consideration			$ 635
Tecnidex Fruit Protection, S.A.U.
Class of Warrant or Right [Line Items]
Cash consideration	$ 20					$ 2.3
Purchase price	$ 22.3
Percentage of voting interests acquired	75.00%
Tecnidex Fruit Protection, S.A.U. | Previously Reported
Class of Warrant or Right [Line Items]
Purchase price	$ 25
Common Stock | AgroFresh Inc.
Class of Warrant or Right [Line Items]
Number of shares issued as consideration (in shares) | shares			17,500,000
Level 3 | Tecnidex Fruit Protection, S.A.U.
Class of Warrant or Right [Line Items]
Contingent consideration	$ 0.7
Adjustment to purchase price allocation					$ 0.4
Tecnidex Fruit Protection, S.A.U. | Tecnidex Fruit Protection, S.A.U.
Class of Warrant or Right [Line Items]
Number of operating countries | country								18

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Jun. 13, 2020
Dow
Related party transactions
Outstanding payable to related party	$ 0	$ 100,000
Other Affiliates | Investment Agreement
Related party transactions
Percent of board required for right to designate directors			50.00%
Percent ownership interest required to designate directors			20.00%
Director | Mutal services agreement
Related party transactions
Expenses paid per service agreement	0
Dow | Dow | Ongoing costs of transition services agreement
Related party transactions
Payment amount for services	$ 40,000	$ 90,000

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw material	$ 3,026	$ 3,401
Work-in-process	8,575	7,278
Finished goods	11,619	10,974
Supplies	1,224	968
Total inventories	$ 24,444	$ 22,621

Other Current Assets (Details)

Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
VAT receivable	$ 7,627	$ 4,925
Prepaid income tax asset	5,349	3,616
Prepaid and other current assets	4,289	3,261
Total other current assets	$ 17,265	$ 11,802

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 23,078		$ 23,078		$ 21,045
Less: accumulated depreciation	(9,803)		(9,803)		(7,868)
Total property and equipment, net	13,275		13,275		13,177
Depreciation expense	700	$ 600	1,900	$ 1,600
Buildings and leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	7,032		$ 7,032		6,508
Buildings and leasehold improvements | Minimum
Property, Plant and Equipment [Line Items]
Useful life (years)			7 years
Buildings and leasehold improvements | Maximum
Property, Plant and Equipment [Line Items]
Useful life (years)			20 years
Machinery & equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	11,953		$ 11,953		10,954
Machinery & equipment | Minimum
Property, Plant and Equipment [Line Items]
Useful life (years)			1 year
Machinery & equipment | Maximum
Property, Plant and Equipment [Line Items]
Useful life (years)			12 years
Furniture
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,944		$ 2,944		2,681
Furniture | Minimum
Property, Plant and Equipment [Line Items]
Useful life (years)			1 year
Furniture | Maximum
Property, Plant and Equipment [Line Items]
Useful life (years)			12 years
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,149		$ 1,149		$ 902

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Goodwill [Roll Forward]
Beginning balance	$ 6,323	$ 6,670
Foreign currency translation	282	(347)
Ending balance	$ 6,605	$ 6,323

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Other intangible assets:
Total intangible assets	$ 856,740		$ 856,740		$ 854,979
Accumulated Amortization	(257,504)		(257,504)		(222,618)
Impairment	0		0		(992)
Total	570,078		570,078
Total intangible assets, net	599,236		599,236		631,369
Amortization of intangibles	10,973	$ 11,754	$ 32,866	$ 35,136
Weighted average
Other intangible assets:
Useful life			14 years 7 months 6 days
Trade name
Other intangible assets:
Gross carrying amount, indefinite-lived	27,158		$ 27,158		27,200
Net, indefinite-lived intangible assets	27,158		27,158		27,200
Service provider network
Other intangible assets:
Gross carrying amount, indefinite-lived	2,000		2,000		2,000
Net, indefinite-lived intangible assets	2,000		2,000		2,000
Developed technology
Other intangible assets:
Gross carrying amount, finite-lived	798,240		798,240		758,760
Accumulated Amortization	(244,918)		(244,918)		(206,998)
Total	553,322		$ 553,322		551,762
Amortization of intangibles					34,000
Developed technology | Weighted average
Other intangible assets:
Useful life			14 years 9 months 18 days
In-process research and development
Other intangible assets:
Gross carrying amount, finite-lived	0		$ 0		39,000
Accumulated Amortization	0		0		(7,222)
Total	0		$ 0		31,778
In-process research and development | Weighted average
Other intangible assets:
Useful life			14 years
Customer relationships
Other intangible assets:
Gross carrying amount, finite-lived	18,551		$ 18,551		18,058
Accumulated Amortization	(3,548)		(3,548)		(2,993)
Total	15,003		$ 15,003		15,065
Customer relationships | Weighted average
Other intangible assets:
Useful life			12 years 1 month 6 days
Software
Other intangible assets:
Gross carrying amount, finite-lived	10,691		$ 10,691		9,861
Accumulated Amortization	(8,967)		(8,967)		(5,347)
Impairment	0		0		(992)
Total	1,724		$ 1,724		3,522
Software | Weighted average
Other intangible assets:
Useful life			1 year
Other
Other intangible assets:
Gross carrying amount, finite-lived	100		$ 100		100
Accumulated Amortization	(71)		(71)		(58)
Total	$ 29		$ 29		$ 42
Other | Weighted average
Other intangible assets:
Useful life			1 year 9 months 18 days

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Future Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Estimated annual amortization expense
2020 (remaining)	$ 12,045		$ 12,045
2021	41,730		41,730
2022	40,893		40,893
2023	40,791		40,791
2024	40,791		40,791
Thereafter	393,828		393,828
Total	570,078		570,078
Amortization of intangibles	$ 10,973	$ 11,754	$ 32,866	$ 35,136

Other Assets (Details)

Other Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Right-of-use asset	$ 5,657	$ 6,599
Long term sales-type lease receivable	2,354	2,501
Other long term receivable	3,438	3,061
Total other assets	$ 11,449	$ 12,161

Accrued and Other Current Lia_3

Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued compensation and benefits	$ 7,111	$ 7,307
Accrued taxes	6,501	3,017
Lease liability	1,368	1,493
Accrued rebates payable	3,001	1,377
Insurance premium financing payable	1,151	1,000
Severance	218	444
Deferred revenue	1,373	1,175
Accrued interest	66	71
Interest rate swap	290	0
Other	5,586	8,466
Total accrued and other current liabilities	$ 26,665	$ 24,350

Debt - Net of Unamortized Disco

Debt - Net of Unamortized Discounts and Deferred Financing Fees (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Jul. 27, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Less: Amounts due within one year	$ 3,316		$ 4,675
Total long-term debt due after one year	264,850		398,064
Loans Payable
Debt Instrument [Line Items]
Loans outstanding	2,184		750
Term loan
Debt Instrument [Line Items]
Loans outstanding	275,000	$ 403,800	405,875
Unamortized deferred issuance costs	$ (9,018)		$ (3,886)

Debt - Narrative (Details)

Debt - Narrative (Details)

Jul. 27, 2020USD ($)

Jul. 31, 2015USD ($)

Sep. 30, 2018USD ($)

Sep. 30, 2020USD ($)

Sep. 30, 2019USD ($)

Sep. 30, 2020USD ($)

Sep. 30, 2019USD ($)

Jul. 31, 2020EUR (€)

May 31, 2020EUR (€)

Mar. 23, 2020EUR (€)

Dec. 31, 2019USD ($)

Jan. 31, 2019USD ($)

Credit facility

Interest rate

7.25%

7.25%

Long term debt, gross

$ 277,184,000

$ 277,184,000

Amortization of deferred financing costs

$ 2,342,000

$ 2,032,000

Payment Protection Program, CARES Act

Credit facility

Forgiveness ineligibility, interest rate

100.00%

100.00%

Forgiveness ineligibility, payment deferral period

6 months

Interest rate swap

Credit facility

Cash flow hedge, gain (loss)

$ 4,000,000

Interest rate swap | Derivative financial instruments, liabilities

Credit facility

Mark-to-market adjustment

$ (300,000)

$ 400,000

Minimum

Credit facility

Commitment fee percentage

0.375%

Minimum | Payment Protection Program, CARES Act

Credit facility

Debt instrument, term

2 years

Maximum

Credit facility

Commitment fee percentage

0.50%

Maximum | Payment Protection Program, CARES Act

Credit facility

Debt instrument, term

5 years

Eurodollar

Credit facility

Margin of interest (as a percent)

6.25%

Eurodollar | Minimum

Credit facility

Margin of interest (as a percent)

6.00%

Eurodollar | Maximum

Credit facility

Margin of interest (as a percent)

6.25%

Base Rate

Credit facility

Margin of interest (as a percent)

5.25%

Term loan

Credit facility

Face amount

$ 275,000,000

$ 425,000,000

275,000,000

$ 275,000,000

€ 600,000

€ 300,000

€ 1,000,000

Interest rate

2.50%

2.20%

1.50%

Extinguishment of debt

107,100,000

Loan balance

403,800,000

275,000,000

275,000,000

$ 405,875,000

Modification of debt

296,700,000

Write off of deferred debt issuance cost

700,000

Unamortized issuance costs

1,900,000

Long term debt, gross

0

0

Debt issuance costs incurred

7,500,000

$ 12,900,000

Amortization of deferred financing costs

200,000

$ 600,000

1,400,000

$ 1,700,000

Deferred issuance costs, net

9,018,000

9,018,000

$ 3,886,000

Fair value of debt

267,400,000

267,400,000

Amortization per year (as a percent)

1.00%

Term loan | Restated Credit Facility

Credit facility

Debt issuance costs incurred

6,400,000

Amortization of deferred financing costs

300,000

Term loan | Existing Lenders

Credit facility

Write off of deferred debt issuance cost

4,400,000

Term loan | New Lenders

Credit facility

Debt issuance costs incurred

1,100,000

Revolving loan

Credit facility

Maximum borrowing available

25,000,000

Long term debt, gross

$ 0

$ 0

Debt issuance costs incurred

500,000

$ 1,300,000

Letter-of-credit sub-facility

Credit facility

Maximum borrowing available

10,000,000

$ 10,000,000

Credit Facility | Alternate base rate

Credit facility

Margin of interest (as a percent)

3.75%

Credit Facility | LIBOR

Credit facility

Margin of interest (as a percent)

4.75%

Variable rate base minimum (as a percent)

1.00%

Bridge Loan

Credit facility

Maximum borrowing available

$ 5,000,000

Debt - Principal Repayments (De

Debt - Principal Repayments (Details) $ in Thousands	Sep. 30, 2020USD ($)
Schedule of principal repayments under the Term Loan
2020 (remaining)	$ 815
2021	3,348
2022	3,390
2023	3,181
2024 and thereafter	266,450
Total	$ 277,184

Leases - Additional Information

Leases - Additional Information on Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Lease, Cost [Abstract]
Operating leases	$ 662	$ 591	$ 1,916	$ 1,849
Short-term lease	6	5	182	52
Total lease expense	$ 668	$ 596	2,098	1,901
Cash payments included in operating cash flows			1,645	1,625
Right-of-use assets obtained in exchange for new lease			$ 769	$ 376
Weighted average discount rate	9.11%	9.33%	9.11%	9.33%
Weighted average remaining lease term in years	5 years 1 month 2 days	5 years 6 months 10 days	5 years 1 month 2 days	5 years 6 months 10 days

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities: Current Period (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Leases [Abstract]
Remainder of 2020	$ 485
2021	1,784	$ 1,939
2022	1,496	1,670
2023	1,228	1,509
2024 and thereafter	2,290
Total undiscounted lease payments	7,283	8,792
Less: present value adjustment	1,450	1,960
Operating lease liability	$ 5,833	$ 6,832

Leases - Maturities of Lease _2

Leases - Maturities of Lease Liabilities: Prior Period (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Leases [Abstract]
2020	$ 1,784	$ 1,939
2021	1,496	1,670
2022	1,228	1,509
2023		1,294
2024 and thereafter		2,380
Total undiscounted lease payments	7,283	8,792
Less: present value adjustment	1,450	1,960
Operating lease liability	$ 5,833	$ 6,832

Other Noncurrent Liabilities (D

Other Noncurrent Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Liabilities, Other than Long-term Debt, Noncurrent [Abstract]
Lease liability	$ 4,465	$ 5,339
Other	1,524	1,907
Total other noncurrent liabilities	$ 5,989	$ 7,246

Severance (Details)

Severance (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Compensation Related Costs [Abstract]
Severance expense	$ 0.4	$ 0.3	$ 0.5	$ 1
Severance liability, current	$ 0.2		$ 0.2		$ 0.4

Series B Convertible Preferre_3

Series B Convertible Preferred Stock and Stockholders' Equity (Details)	Jun. 13, 2020$ / shares	Jul. 31, 2015directorshares	Jul. 27, 2020shares	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Dec. 31, 2020USD ($)shares	Sep. 30, 2020USD ($)vote$ / sharesshares	Sep. 30, 2019USD ($)	Dec. 31, 2015shares	Jun. 25, 2020shares	Dec. 31, 2019USD ($)$ / sharesshares	Feb. 28, 2014shares
Class of Warrant or Right [Line Items]
Authorized common stock (in shares)				400,000,000			400,000,000				400,000,000
Par value of common stock (in dollars per share) | $ / shares				$ 0.0001			$ 0.0001				$ 0.0001
Number of votes entitled by holders of common stock for each share of common stock | vote							1
Common stock, shares outstanding (in shares)				52,393,579			52,393,579				51,178,146
Number of shares issuable upon exercise of warrants (in shares)				15,983,072			15,983,072
Exercise price (in dollars per share) | $ / shares				$ 11.50			$ 11.50
Number of warrants outstanding (in shares)				15,983,072			15,983,072
Preferred stock, par value (in dollars per share) | $ / shares				$ 0.0001			$ 0.0001				$ 0.0001
Rohm and Haas
Class of Warrant or Right [Line Items]
Number of shares of Series A Preferred Stock issued as condition to consummation of business combination (in shares)		1
Number of directors preferred stockholder is entitled to appoint if minimum ownership percentage of common stock is maintained | director		1
Minimum percentage of outstanding shares of voting and non-voting common stock to be held to entitle preferred stockholder to appoint director		10.00%
Series B Convertible Stock
Class of Warrant or Right [Line Items]
Preferred stock, par value (in dollars per share) | $ / shares				$ 0.0001			$ 0.0001				$ 0.0001
Dividends | $				$ 4,400,000	$ 0		$ 4,400,000	$ 0
Accrued dividends | $				$ 0			$ 0				$ 0
Preferred stock, convertible, conversion price (in dollars per share) | $ / shares	$ 5
Series B Convertible Stock | Maximum
Class of Warrant or Right [Line Items]
Preferred stock issued (in shares)				30,440,000			30,440,000				0
Series B Convertible Stock | Paid In-Kind
Class of Warrant or Right [Line Items]
Dividends | $				$ 2,200,000			$ 2,200,000
Series B Convertible Stock | Cash
Class of Warrant or Right [Line Items]
Dividends | $				$ 2,200,000			$ 2,200,000
Public warrants
Class of Warrant or Right [Line Items]
Number of warrants outstanding (in shares)												9,823,072
Number of warrants repurchased (in shares)									1,201,928
Private placement warrants
Class of Warrant or Right [Line Items]
Number of warrants outstanding (in shares)												6,160,000
Dividend rate increase	2.00%
Private placement warrants | Dividends Within First Anniversary
Class of Warrant or Right [Line Items]
Percentage payable in cash	50.00%
Percentage payable in kind	50.00%
Private placement warrants | Dividends After First Anniversary
Class of Warrant or Right [Line Items]
Percentage payable in cash	50.00%
Percentage payable in kind	37.50%
Percentage payable in cash or kind	12.50%
Private placement warrants | Convertible Preferred Stock | Forecast
Class of Warrant or Right [Line Items]
Sale of stock, consideration received on transaction | $						$ 150,000,000
Private placement warrants | Series B Convertible Stock
Class of Warrant or Right [Line Items]
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001
Liquidation preference (in dollars per share) | $ / shares	1,000
Private placement warrants | Series B Convertible Stock | Forecast
Class of Warrant or Right [Line Items]
Preferred stock issued (in shares)						150,000
Convertible preferred stock, shares issued upon conversion (in shares)						150,000
Cumulative dividend rate						16.00%
Private placement warrants | Series B-1 Convertible Preferred Stock
Class of Warrant or Right [Line Items]
Preferred stock issued (in shares)			150,000
Preferred stock, par value (in dollars per share) | $ / shares	0.0001
Liquidation preference (in dollars per share) | $ / shares	1,000
Private placement warrants | Series B-1 Convertible Preferred Stock | Forecast
Class of Warrant or Right [Line Items]
Cumulative dividend rate						16.00%
Private placement warrants | Series B-2 Convertible Preferred Stock
Class of Warrant or Right [Line Items]
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001
ATM Facility
Class of Warrant or Right [Line Items]
Authorized common stock (in shares)										30,000,000

Series B Convertible Preferre_4

Series B Convertible Preferred Stock and Stockholders' Equity - Temporary Equity (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)shares
Series B Convertible Stock
Temporary Equity [Line Items]
Balance at beginning of period (in shares) | shares	0
Balance at beginning of period	$ 0
Issuance of preferred stock (in shares) | shares	150,000
Issuance of preferred stock	$ 150,000
Exchange to Series B preferred stock (in shares) | shares	0
Exchange to Series B preferred stock	$ 0
Issuance-related expenses	$ (11,516)
Additional preferred shares (in shares) | shares	0
Additional preferred shares	$ 2,200
Balance at end of period (in shares) | shares	150,000
Balance at end of period	$ 140,684
Series B-1 Convertible Preferred Stock
Temporary Equity [Line Items]
Balance at beginning of period (in shares) | shares	0
Balance at beginning of period	$ 0
Issuance of preferred stock (in shares) | shares	150,000
Issuance of preferred stock	$ 150,000
Exchange to Series B preferred stock (in shares) | shares	(150,000)
Exchange to Series B preferred stock	$ (150,000)
Issuance-related expenses	$ 0
Additional preferred shares (in shares) | shares	0
Additional preferred shares	$ 0
Balance at end of period (in shares) | shares	0
Balance at end of period	$ 0
Series B-2 Convertible Preferred Stock
Temporary Equity [Line Items]
Balance at beginning of period (in shares) | shares	0
Balance at beginning of period	$ 0
Issuance of preferred stock (in shares) | shares	150,000
Issuance of preferred stock	$ 0
Exchange to Series B preferred stock (in shares) | shares	(150,000)
Exchange to Series B preferred stock	$ 0
Issuance-related expenses	$ 0
Additional preferred shares (in shares) | shares	0
Additional preferred shares	$ 0
Balance at end of period (in shares) | shares	0
Balance at end of period	$ 0

Stock-based Compensation - Narr

Stock-based Compensation - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2019	Jul. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized (in shares)						7,150,000
Stock-based compensation expense	$ 0.9	$ 1	$ 2.7	$ 2.1
Share-based compensation, nonvested awards, compensation cost not yet recognized	$ 5.3		$ 5.3
Period for recognition of compensation on unvested stock option (in years)			1 year 10 months 24 days
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized (in shares)					500,000
Shares issued (in shares)			253,042

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Weighted Average Common Shares Outstanding (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
Basic weighted-average common shares outstanding (in shares)	51,001,852	50,227,590	50,765,829	50,138,835
Effect of dilutive options, performance stock units and restricted stock (in shares)	0	60,714	0	0
Dilute weighted-average shares outstanding (in shares)	51,001,852	50,288,304	50,765,829	50,138,835

Earnings Per Share (Details)

Earnings Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Stock options
Earnings Per Share [Line Items]
Antidilutive securities (in shares)	799,570	1,028,583	804,267	949,987
Warrants | Private placement warrants
Earnings Per Share [Line Items]
Antidilutive securities (in shares)	2,075,652	6,160,000	4,788,613	6,160,000
Warrants | Public warrants
Earnings Per Share [Line Items]
Antidilutive securities (in shares)	3,309,948	9,823,072	7,636,184	9,823,072
Non-Director | Restricted stock
Earnings Per Share [Line Items]
Antidilutive securities (in shares)	1,811,016	749,510	1,079,151	624,930

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Valuation allowance	$ 24.7		$ 24.7
Effective tax rate (as a percent)	743.90%	214.00%	(111.70%)	28.20%

Segment Information (Details)

Segment Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)segment	Sep. 30, 2019USD ($)
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of operating segments | segment			2
Number of reportable segments | segment			2
Net sales	$ 52,770	$ 48,972	$ 105,775	$ 109,095
Gross Profit	39,259	35,080	77,283	77,579
AgroFresh Core
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Net sales	49,343	45,917	94,723	96,272
Gross Profit	38,283	34,182	73,080	72,679
Tecnidex
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Net sales	3,427	3,055	11,052	12,823
Gross Profit	$ 976	$ 898	$ 4,203	$ 4,900

Commitment and Contingencies (D

Commitment and Contingencies (Details) $ in Millions	Oct. 14, 2019USD ($)	Jul. 31, 2020numberOfLawsuits
Loss Contingencies [Line Items]
Number of class action lawsuits filed | numberOfLawsuits		3
Unfavorable Regulatory Action
Loss Contingencies [Line Items]
Damages awarded | $	$ 31.1

Fair Value Measurements - Finan

Fair Value Measurements - Financial Instruments Measured on a Recurring Basis (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Phantom Stock Units
Financial instruments measured at fair value on a recurring basis
Expected dividends	$ 0
Minimum | Phantom Stock Units
Financial instruments measured at fair value on a recurring basis
Grant date fair value (in dollars per share)	$ 1.70
Risk-free interest rate	0.27%
Expected life (years)	2 years 8 months 15 days
Estimated volatility factor (percent)	65.10%
Maximum | Phantom Stock Units
Financial instruments measured at fair value on a recurring basis
Grant date fair value (in dollars per share)	$ 7.28
Risk-free interest rate	2.39%
Expected life (years)	2 years 9 months
Estimated volatility factor (percent)	69.90%
Recurring
Financial instruments measured at fair value on a recurring basis
Fair value of liability	$ 584,000	$ 123,000
Recurring | Level 1
Financial instruments measured at fair value on a recurring basis
Fair value of liability	0	0
Recurring | Level 2
Financial instruments measured at fair value on a recurring basis
Fair value of liability	0	0
Recurring | Level 3
Financial instruments measured at fair value on a recurring basis
Fair value of liability	584,000	123,000
Liability-classified stock compensation | Recurring
Financial instruments measured at fair value on a recurring basis
Fair value of liability	294,000	218,000
Liability-classified stock compensation | Recurring | Level 1
Financial instruments measured at fair value on a recurring basis
Fair value of liability	0	0
Liability-classified stock compensation | Recurring | Level 2
Financial instruments measured at fair value on a recurring basis
Fair value of liability	0	0
Liability-classified stock compensation | Recurring | Level 3
Financial instruments measured at fair value on a recurring basis
Fair value of liability	294,000	218,000
Derivative financial instruments, liabilities | Recurring | Interest rate swap
Financial instruments measured at fair value on a recurring basis
Fair value of liability	290,000	(95,000)
Derivative financial instruments, liabilities | Recurring | Level 1 | Interest rate swap
Financial instruments measured at fair value on a recurring basis
Fair value of liability	0	0
Derivative financial instruments, liabilities | Recurring | Level 2 | Interest rate swap
Financial instruments measured at fair value on a recurring basis
Fair value of liability	0	0
Derivative financial instruments, liabilities | Recurring | Level 3 | Interest rate swap
Financial instruments measured at fair value on a recurring basis
Fair value of liability	$ 290,000	$ (95,000)

Fair Value Measurements - Chang

Fair Value Measurements - Changes of Level 3 Financial Instruments (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2020USD ($)	Sep. 30, 2020USD ($)
Level 3
Financial instruments measured at Level 3 fair value on a recurring basis rollforward
Balance, beginning period		$ 123
Stock compensation activity		76
Mark-to-market adjustment		385
Balance, ending period	$ 584	584
Liability-classified stock compensation | Level 3
Financial instruments measured at Level 3 fair value on a recurring basis rollforward
Balance, beginning period		218
Stock compensation activity		76
Mark-to-market adjustment		0
Balance, ending period	294	294
Derivative financial instruments, liabilities | Interest rate swap
Financial instruments measured at Level 3 fair value on a recurring basis rollforward
Mark-to-market adjustment	300	(400)
Derivative financial instruments, liabilities | Interest rate swap | Level 3
Financial instruments measured at Level 3 fair value on a recurring basis rollforward
Balance, beginning period		(95)
Stock compensation activity		0
Mark-to-market adjustment		385
Balance, ending period	290	290
Term loan
Financial instruments measured at Level 3 fair value on a recurring basis
Fair value of debt	$ 267,400	$ 267,400